Sangamo Therapeutics（SGMO）株式概要Sangamo Therapeutics, Inc.は臨床段階のゲノム医療企業であり、米国で重篤な疾患に苦しむ患者やその家族の生活を変革する医薬品に科学を転換することに注力している。 詳細SGMO ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長5/6過去の実績0/6財務の健全性1/6配当金0/6報酬当社が推定した公正価値より99.3%で取引されている 収益は年間65.16%増加すると予測されています リスク分析キャッシュランウェイが1年未満である マイナスの株主資本 過去1年間で株主の希薄化は大幅に進んだ US市場と比較して、過去 3 か月間の株価の変動が非常に大きい+1 さらなるリスクすべてのリスクチェックを見るSGMO Community Fair Values Create NarrativeSee what 38 others think this stock is worth. Follow their fair value or set your own to get alerts.Analyst Price TargetsAN95.2% undervaluedAnalystConsensusTarget•3mo agoFDA Approval In 2026 Will Extend Fabry Gene Therapy Prospects972020AN84.4% undervaluedAnalystLowTarget•1mo agoRising Funding Needs Will Threaten Fabry Trials And Inspire Hope15103AN98.4% undervaluedAnalystHighTarget•9mo agoAging Populations And AI Integration Will Expand Gene Therapy Markets4900Top Analyst NarrativesAN95.2% undervaluedAnalystConsensusTarget•3mo agoFDA Approval In 2026 Will Extend Fabry Gene Therapy Prospects972020AN84.4% undervaluedAnalystLowTarget•1mo agoRising Funding Needs Will Threaten Fabry Trials And Inspire Hope15103AN98.4% undervaluedAnalystHighTarget•9mo agoAging Populations And AI Integration Will Expand Gene Therapy Markets4900View all narrativesSangamo Therapeutics, Inc. 競合他社Seres TherapeuticsSymbol: NasdaqGS:MCRBMarket cap: US$74.2mAligos TherapeuticsSymbol: NasdaqCM:ALGSMarket cap: US$34.7mTScan TherapeuticsSymbol: NasdaqGM:TCRXMarket cap: US$65.0mKyntra BioSymbol: NasdaqGS:KYNBMarket cap: US$28.1m価格と性能株価の高値、安値、推移の概要Sangamo Therapeutics過去の株価現在の株価US$0.1652週高値US$0.7752週安値US$0.10ベータ1.041ヶ月の変化-39.42%3ヶ月変化-59.46%1年変化-68.45%3年間の変化-88.27%5年間の変化-98.56%IPOからの変化-98.96%最新ニュースお知らせ • May 12Sangamo Therapeutics, Inc. to Report Q1, 2026 Results on May 14, 2026Sangamo Therapeutics, Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 14, 2026お知らせ • May 06Sangamo Therapeutics, Inc.(OTCPK:SGMO) dropped from NASDAQ Composite IndexSangamo Therapeutics, Inc. has been dropped from the NASDAQ Composite Index.お知らせ • Apr 30+ 1 more updateSangamo Therapeutics, Inc. Presents Pipeline And Technology Advances At The American Society Of Gene & Cell Therapy Annual MeetingSangamo Therapeutics, Inc. announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted three Sangamo abstracts for presentation at the 29th ASGCT Annual Meeting being held May 11-15, 2026, in-person in Boston, MA and in a virtual format. Presentations will highlight the progression of Sangamo’s neurology pipeline, including advances in zinc finger epigenetic regulation and developments in modular integrase technology. Presentations at the ASGCT Annual Meeting include two posters detailing Sangamo’s advances in the application of zinc finger repressors (ZFRs) as a novel class of epigenetic regulation for neurological disease targets – specifically in chronic neuropathic pain and in prion disease. A platform presentation will showcase updated data from Sangamo’s protein-guided MINT platform as an approach to integrate large sequences of DNA into the genome to potentially treat, with a single medicine, many different patients who have unique mutations in the same gene. The MINT platform could be deployed internally for neurology-focused indications, and could provide potential new collaboration opportunities, both for human disease and in agricultural biotech settings. Neurology Epigenetic Regulation: ST-503 nonclinical safety studies evaluating zinc finger repressors regulating the expression of the Nav1.7 gene for treatment of small fiber neuropathy. Abstract No. 1309. Poster Presentation – Tuesday, May 12, 5:00-6:30pm EDT. Single-cell characterization of ST-506, a BBB-penetrant epigenetic repressor of Prion protein expression, in the nonhuman primate brain. Abstract No. 1469. Poster Presentation – Tuesday, May 12, 5:00-6:30pm EDT. Next-Generation Genome Engineering: Zinc finger fusions and synthetic DNA donor engineering improve the performance of reprogrammed modular integrases at the TRAC locus. Abstract No. 105. Oral Presentation – Tuesday, May 12, 4:00-4:15pm EDT. Session Name: Next-generation platforms for precise therapeutic genome editing and integration.ナラティブの更新 • Apr 20SGMO: Fabry Filing Progress Will Offset Going Concern And Liquidity FearsAnalysts have updated their price target on Sangamo Therapeutics to reflect revised assumptions for the discount rate, revenue growth, profit margin and future P/E. The new fair value estimate remains at $1.00, in line with the prior $1.00 target.Major Estimate Revision • Apr 07Consensus revenue estimates increase by 22%The consensus outlook for revenues in fiscal year 2026 has improved. 2026 revenue forecast increased from US$55.4m to US$67.6m. Forecast losses expected to reduce from -US$0.245 to -US$0.153 per share. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target broadly unchanged at US$3.75. Share price rose 3.7% to US$0.26 over the past week.ナラティブの更新 • Apr 06SGMO: Fabry Gene Therapy Filing And Diagnostic Will Drive Future UpsideAnalysts have trimmed their price target on Sangamo Therapeutics from $1.25 to $1.00, citing updated assumptions for revenue growth, profit margins and future P/E that have reset expectations for the stock. What's in the News Sangamo reported unaudited impairment charges on long lived assets of US$13,235,000 for the fourth quarter ended December 31, 2025, which affects reported earnings quality for that period (Key Developments).最新情報をもっと見るRecent updatesお知らせ • May 12Sangamo Therapeutics, Inc. to Report Q1, 2026 Results on May 14, 2026Sangamo Therapeutics, Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 14, 2026お知らせ • May 06Sangamo Therapeutics, Inc.(OTCPK:SGMO) dropped from NASDAQ Composite IndexSangamo Therapeutics, Inc. has been dropped from the NASDAQ Composite Index.お知らせ • Apr 30+ 1 more updateSangamo Therapeutics, Inc. Presents Pipeline And Technology Advances At The American Society Of Gene & Cell Therapy Annual MeetingSangamo Therapeutics, Inc. announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted three Sangamo abstracts for presentation at the 29th ASGCT Annual Meeting being held May 11-15, 2026, in-person in Boston, MA and in a virtual format. Presentations will highlight the progression of Sangamo’s neurology pipeline, including advances in zinc finger epigenetic regulation and developments in modular integrase technology. Presentations at the ASGCT Annual Meeting include two posters detailing Sangamo’s advances in the application of zinc finger repressors (ZFRs) as a novel class of epigenetic regulation for neurological disease targets – specifically in chronic neuropathic pain and in prion disease. A platform presentation will showcase updated data from Sangamo’s protein-guided MINT platform as an approach to integrate large sequences of DNA into the genome to potentially treat, with a single medicine, many different patients who have unique mutations in the same gene. The MINT platform could be deployed internally for neurology-focused indications, and could provide potential new collaboration opportunities, both for human disease and in agricultural biotech settings. Neurology Epigenetic Regulation: ST-503 nonclinical safety studies evaluating zinc finger repressors regulating the expression of the Nav1.7 gene for treatment of small fiber neuropathy. Abstract No. 1309. Poster Presentation – Tuesday, May 12, 5:00-6:30pm EDT. Single-cell characterization of ST-506, a BBB-penetrant epigenetic repressor of Prion protein expression, in the nonhuman primate brain. Abstract No. 1469. Poster Presentation – Tuesday, May 12, 5:00-6:30pm EDT. Next-Generation Genome Engineering: Zinc finger fusions and synthetic DNA donor engineering improve the performance of reprogrammed modular integrases at the TRAC locus. Abstract No. 105. Oral Presentation – Tuesday, May 12, 4:00-4:15pm EDT. Session Name: Next-generation platforms for precise therapeutic genome editing and integration.ナラティブの更新 • Apr 20SGMO: Fabry Filing Progress Will Offset Going Concern And Liquidity FearsAnalysts have updated their price target on Sangamo Therapeutics to reflect revised assumptions for the discount rate, revenue growth, profit margin and future P/E. The new fair value estimate remains at $1.00, in line with the prior $1.00 target.Major Estimate Revision • Apr 07Consensus revenue estimates increase by 22%The consensus outlook for revenues in fiscal year 2026 has improved. 2026 revenue forecast increased from US$55.4m to US$67.6m. Forecast losses expected to reduce from -US$0.245 to -US$0.153 per share. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target broadly unchanged at US$3.75. Share price rose 3.7% to US$0.26 over the past week.ナラティブの更新 • Apr 06SGMO: Fabry Gene Therapy Filing And Diagnostic Will Drive Future UpsideAnalysts have trimmed their price target on Sangamo Therapeutics from $1.25 to $1.00, citing updated assumptions for revenue growth, profit margins and future P/E that have reset expectations for the stock. What's in the News Sangamo reported unaudited impairment charges on long lived assets of US$13,235,000 for the fourth quarter ended December 31, 2025, which affects reported earnings quality for that period (Key Developments).お知らせ • Apr 01Sangamo Therapeutics, Inc. Reports Unaudited consolidated Impairment Charges for the Fourth Quarter Ended December 31, 2025Sangamo Therapeutics, Inc. reported Unaudited consolidated impairment charges for the fourth quarter ended December 31, 2025. For the period, the company reported impairment of long-lived assets of $13,235,000.Reported Earnings • Mar 31Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: US$0.44 loss per share. Revenue: US$39.6m (down 32% from FY 2024). Net loss: US$122.9m (loss widened 26% from FY 2024). Revenue missed analyst estimates by 40%. Earnings per share (EPS) also missed analyst estimates by 42%. Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.ナラティブの更新 • Mar 22SGMO: Fabry Gene Therapy Filing And Kidney Endpoint Will Drive UpsideAnalysts have adjusted their price target on Sangamo Therapeutics to $1.25, with the change based on updated views on discount rate, revenue growth, profit margin, and future P/E assumptions, even though the fair value estimate itself remains $1.25. What's in the News Sangamo started a rolling submission of a Biologics License Application to the FDA for isaralgagene civaparvovec (ST-920), an investigational one time gene therapy for adults with Fabry disease, and has submitted the preclinical and clinical modules for review (Key Developments).お知らせ • Mar 20Sangamo Therapeutics, Inc. to Report Q4, 2025 Results on Mar 30, 2026Sangamo Therapeutics, Inc. announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on Mar 30, 2026お知らせ • Mar 10Sangamo Therapeutics, Inc. Advances Rolling Submission Of BLA To U.S. FDA For ST-920 In Fabry DiseaseSangamo Therapeutics, Inc. announced advancement of the rolling submission of a BLA to the FDA seeking accelerated approval of isaralgagene civaparvovec, or ST-920, a wholly owned investigational gene therapy for the treatment of adults with Fabry disease. Following initiation of the rolling submission in December 2025, Sangamo has now submitted the preclinical and clinical modules to the FDA for review. Rolling submission allows for completed modules of the BLA to be submitted and reviewed by the FDA on an ongoing basis rather than waiting for the entire BLA to be submitted at once. In addition, the antibody assay companion diagnostic, which is designed to screen patients for eligibility with isaralgagene civaparvovec, has been submitted to, and accepted by, the FDA’s Center for Devices and Radiological Health (CDRH) seeking Premarket Approval (PMA). The STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which the FDA has agreed will serve as endpoint to support accelerated approval. These data were presented via four platform presentations and in poster presentations at the recent 22nd Annual WORLDSymposium™. These data are available on Sangamo’s website on the Presentations page. The Phase 1/2 STAAR study is a global open-label, single-dose, dose-ranging, multicenter clinical study designed to evaluate isaralgagene civaparvovec, or ST-920, a gene therapy product candidate in patients with Fabry disease. Isaralgagene civaparvovec requires a one-time infusion without preconditioning. Isaralgagene civaparvovec has been granted Orphan Drug, Fast Track and RMAT designations from the FDA, Orphan Medicinal Product designation and PRIME eligibility from the European Medicines Agency and Innovative Licensing and Access Pathway from U.K. Medicines and Healthcare products Regulatory Agency. Fabry disease is a lysosomal storage disorder caused by mutations in the galactosidase alpha gene (GLA), which leads to deficient alpha-galactosidase A (a-Gal A) enzyme activity, which is necessary for metabolizing globotriaosylceramide (Gb3). The buildup of Gb3 in the cells can cause serious damage to vital organs, including the kidney, heart, nerves, eyes, gut and skin. Symptoms of Fabry disease can include decreased or absent sweat production, heat intolerance, angiokeratoma (skin blemishes), vision problems, kidney disease, heart failure, gastrointestinal disturbance, mood disorders, neuropathic pain and tingling in the extremities.ナラティブの更新 • Mar 08SGMO: Accelerated Approval Pathway On Kidney Data Will Drive Bullish UpsideAnalysts have set their price target for Sangamo Therapeutics at $1.25, based on updated assumptions for discount rate, revenue growth, profit margin, and future P/E, while the fair value estimate remains unchanged at $1.25. What's in the News Sangamo reported detailed data from the registrational Phase 1/2 STAAR study of its gene therapy candidate isaralgagene civaparvovec (ST 920) for Fabry disease.ナラティブの更新 • Feb 22SGMO: Accelerated Approval On Kidney Function Data Will Drive Bullish ThesisAnalysts have maintained their average price target for Sangamo Therapeutics at $1.25. This reflects minor adjustments to their models, including slightly different assumptions for discount rate, revenue growth, profit margin, and forward P/E, rather than a change in their overall view.ナラティブの更新 • Feb 07SGMO: Accelerated Approval Using EGFR Slope Will Support Bullish OutlookAnalysts have nudged their fair value estimate for Sangamo Therapeutics higher to $1.25 from $1.00, citing updated assumptions around revenue growth, profit margins, discount rates and a higher future P/E multiple. What's in the News Sangamo Therapeutics completed a follow on equity offering totaling approximately US$24.8 million, issuing 35,190,292 shares of common stock at US$0.4719 per share and 17,787,033 pre funded warrants at US$0.4619 per warrant (Key Developments).お知らせ • Feb 04Sangamo Therapeutics, Inc. Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium 2026Sangamo Therapeutics, Inc. announced detailed data from the registrational Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease. These data will be presented via four platform presentations and in poster presentations at the 22nd Annual WORLDSymposium taking place in San Diego, CA, February 2-6, 2026.Sangamo believes that the totality of data from the registrational STAAR study demonstrates the potential of isaralgagene civaparvovec as a one-time, well-tolerated and durable gene therapy treatment option for Fabry disease to provide meaningful, multi-organ clinical benefits that could fundamentally shift the Fabry treatment paradigm. As of the April 10, 2025 data cut-off date, a positive mean annualized eGFR slope of 1.965 mL/min/1.73m/year (95% confidence interval (CI): -0.153, 4.083) at 52-weeks was observed across all 32 dosed patients, indicating an improvement in renal function. Furthermore, a mean annualized eGFR slope of 1.747 mL/min/1.73m/year (95% CI: -0.106, 3.601) was observed for the 19 patients who had achieved 104-weeks of follow-up. Stable cardiac function was observed over one year, including consistent cardiac structural stability across clinical and demographic subgroups. Durability of effect was demonstrated with elevated expression of alpha-galactosidase A (a-Gal A) activity maintained for up to 4.5 years for the longest treated patient, alongside statistically significant Quality of Life improvements and other clinical benefits. Isaralgagene civaparvovec demonstrated a favorable safety and tolerability profile in the study, without the requirement for preconditioning. The Phase 1/2 STAAR Study is complete, and 32 patients have successfully rolled into the long-term follow-up study. The FDA has provided a clear regulatory pathway to Accelerated Approval for isaralgagene Civaparvovec, agree that data from the ongoing Phase 1/2 STAAR trial can serve as the primary basis for approval under the Accelerated Approval Program, using mean annualized eGFR slope at 52 weeks as an intermediate clinical endpoint. In December 2025, Sangamo initiated a rolling submission of a BLA to the FDA seeking approval of isaralgagene civAParvovec under an Accelerated Approval pathway.お知らせ • Feb 03Sangamo Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $24.822129 million.Sangamo Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $24.822129 million. Security Name: common Stock Security Type: Common Stock Securities Offered: 35,190,292 Price\Range: $0.4719 Discount Per Security: $0.0283 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 17,787,033 Price\Range: $0.4619 Discount Per Security: $0.0277分析記事 • Feb 03Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Share Price Boosted 29% But Its Business Prospects Need A Lift TooSangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares have had a really impressive month, gaining 29% after a shaky period...New Risk • Jan 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$76m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Shareholders have been substantially diluted in the past year (61% increase in shares outstanding).ナラティブの更新 • Jan 23SGMO: Accelerated Approval Pathway Will Drive Upside Despite Downgrade Through 2026Narrative Update Analysts have cut their price target on Sangamo Therapeutics from US$5 to US$1, citing the recent downgrade to Equal Weight and a wait for more clarity on a potential Fabry deal, despite the FDA reaffirming an accelerated approval path and the company extending its cash runway into Q1 2026. Analyst Commentary Recent research paints a mixed picture for Sangamo Therapeutics, with the lower price target and rating downgrade balanced against some supportive clinical and balance sheet signals.ナラティブの更新 • Jan 09SGMO: Accelerated Approval Path Using EGFR Slope Will Drive Future UpsideAnalysts have trimmed their 12 month price target on Sangamo Therapeutics to US$1 from US$5, citing a wait and see stance on Fabry deal clarity and the current cash runway into Q1 2026, despite the reaffirmed accelerated approval path using eGFR slope. Analyst Commentary Bearish analysts are signaling a more cautious stance on Sangamo Therapeutics after the recent Q3 update, with the sharp cut in the 12 month price target standing out as a key marker of reduced confidence.ナラティブの更新 • Dec 25SGMO: Accelerated Approval Pathway And Extended Runway Will Support Upside Through 2026Analysts have modestly reduced their price target on Sangamo Therapeutics to $1 from $5, citing a more cautious stance as they await greater clarity on potential Fabry partnership developments, despite the extended cash runway and reaffirmed accelerated approval pathway. Analyst Commentary Analysts note that the downgrade and lower price target reflect a shift toward a more balanced risk reward profile, with recent catalysts prompting both supportive and cautious views on Sangamo Therapeutics.お知らせ • Dec 18Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry DiseaseSangamo Therapeutics, Inc. has initiated a rolling submission of a BLA to the FDA seeking accelerated approval of isaralgagene civaparvovec, or ST-920, a wholly owned investigational gene therapy for the treatment of adults with Fabry disease. Rolling submission allows for completed modules of the BLA to be submitted and reviewed by the FDA on an ongoing basis rather than waiting for the entire BLA to be submitted at once. Furthermore, the STAAR study demonstrated a positive mean annualized eGFR slope at 52-we weeks across all dosed patients in the study, which the FDA has agreed will serve as endpoint to support accelerated approval. Isaralgagene civapARvovec has been granted Orphan Drug, Fast Track and RMAT designations from the FDA, Orphan Medicinal Product designation and PRIME eligibility from the European Medicines Agency and Innovative Licensing and Access Pathway from U.K. Medicines and Healthcare products Regulatory Agency. Sangamo expects to complete submission of the BLA to the FDA under the accelerated approval pathway in the second quarter of 2026. Sangamo believes that its zinc finger epigenetic regulators are ideally suited to potentially address devastating neurological disorders and that its capsid discovery platform can expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system. These forward-looking statements include, without limitation, statements relating to: the safety and efficacy and therapeutic potential of isaralgagene Civaparvovec, including the potential for it to be a one-time, durable treatment option for Fabry disease to provide meaningful, multi-organ clinical benefits above current standards of care; the potential for isaralgagene civapearvovec to qualify for the FDA's accelerated approval program, including the adequacy of data generated in the Phase 1/2 STAAR study to support any such approval; expectations regarding the availability of additional data to support a potential BLA submission for isaralgagene Civapearvovec, and the timing of such submission; and other statements that are not historical fact. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to Sangamo's lack of capital resources to obtain regulatory approval for and commercialize its product candidates in a timely manner or at all, including the ability to secure a commercialization partner for ST-920; the uncertain timing and unpredictable nature of clinical trial results, including the risk that preliminary or topline data is not indicative of final results, that the therapeutic effects observed in the latest clinical data from the Phase 1/2 STAar study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civilaparvovec,including that the 52-week data from the Phase 1/2 STAAR study will not support a BLA submission and/or that the 104-week data from such study will not verify the clinical benefit of isaralgagene civicaparvovec or support FDA approval, and that the patients withdrawn from ERT will remain off ERT; All forward-looking statements about Sangamo's future plans and expectations, including Sangamo's development plans for its product candidates, are subject to Sangamo's ability to secure adequate additional funding. There can be no assurance that Sangamo and its current or potential future partners will be able to develop a clinical trial data from the Phase 1/1/2 STAAR study will not support the clinical benefit of isaralagene civaparvovovec or support FDA approval.ナラティブの更新 • Dec 11SGMO: Accelerated Approval Pathway Is Expected To Drive Upside Through 2026Analysts have lowered their price target on Sangamo Therapeutics from $5.00 to $1.00 per share, citing a more cautious stance as they await greater clarity on a potential Fabry partnership, despite an extended cash runway and a reaffirmed accelerated approval path. Analyst Commentary Analysts are reassessing Sangamo Therapeutics with a more balanced view, emphasizing both the company’s de-risked regulatory path and the uncertainties that could weigh on execution and valuation.Breakeven Date Change • Dec 07Forecast to breakeven in 2027The 4 analysts covering Sangamo Therapeutics expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 11% per year to 2026. The company is expected to make a profit of US$15.7m in 2027. Average annual earnings growth of 72% is required to achieve expected profit on schedule.お知らせ • Dec 02Sangamo Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber NeuropathySangamo Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ST-503, an investigational epigenetic regulator for the treatment of intractable pain due to small fiber neuropathy (SFN), a type of chronic neuropathic pain. Fast Track Designation aims to facilitate the development and expedite the review of new therapeutics that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Companies granted this designation are given the opportunity for more frequent interactions with the FDA. These clinical programs may also be eligible to apply for Accelerated Approval and Priority Review if relevant criteria are met. ST-503 is currently being evaluated in the Phase 1/2 STAND study, where patient recruitment and enrollment are in progress. In September 2025, Sangamo presented updated nonclinical data highlighting the pharmacology and safety of ST-503 in chronic neuropathic pain at the 9th International Congress on Neuropathic Pain. The data demonstrated the durability, potency and selectivity of ST-503 in nonhuman primates, alongside a favorable safety profile, supporting its development for the treatment of chronic neuropathic pain. A copy of the presentation is available in the Presentations section of the Sangamo website. Ant antidepressantsants, anticonvulsants, opioids and topical therapies are potential treatment options, although no long-lasting or curative therapies are currently available for SFN patients, leading to a high unmet medical need for this patient population.ナラティブの更新 • Nov 27SGMO: FDA Accelerated Pathway Will Extend Bullish Momentum Into 2026Analysts have lowered Sangamo Therapeutics’ price target from $5 to $1, citing uncertainty around future partnership deals. This is despite recent regulatory updates and an extended cash runway.分析記事 • Nov 23Revenues Working Against Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Share Price Following 33% DiveSangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares have had a horrible month, losing 33% after a relatively good period...お知らせ • Nov 22Sangamo Therapeutics, Inc. Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry DiseaseSangamo Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted Sangamo's request for a rolling submission and review of the Biologics License Application (BLA) for isaralgagene civaparvovec, or ST-920, a wholly owned investigational gene therapy for the treatment of adults with Fabry disease. This acceptance follows Sangamo's meeting with the FDA in October 2025 to discuss the proposed efficacy and safety data package for isaralgagene Civaparvovec where, in the meeting minutes, among other things, the FDA reiterated its October 2024 agreement to use eGFR slope as an endpoint to support an accelerated approval pathway. Sangamo presented detailed clinical data from the registrational Phase 1/2 STAAR study at the International Congress of Inborn Errors of Metabolism 2025 (ICIEM2025) in September, which demonstrated the potential for isaralgagene civilaparvovec as a one-time, durable treatment of underlying pathology of Fabry disease to provide meaningful, multi-organ, clinical benefits above current standards of care. Furthermore, the STAAR study demonstrated a positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-we weeks across allosed patients in the study, which the FDA has agreed will serve as the primary basis of approval. Isaralgagene civapARvovec has been granted Orphan Drug, Fast Track and RMAT designations from the FDA, Orphan Medicinal Product designation and PRIME eligibility from the European Medicines Agency and Innovative Licensing and Access Pathway from U.K. Medicines and Healthcare products Regulatory Agency. Sangamo plans to initiate rolling submission of the BLA to the FDA under the accelerated approval pathway later in the fourth quarter of 2025. These forward-looking statements include, without limitation, statements relating to: the safety and efficacy and therapeutic potential of isaralgagene civAParvovec, including the potential for isaralgAGene civaparvoveC, including that the 52-week data from the Phase 1/2 STAAR trial will not support a BLA submission and/or that the 104-week data from such study will not verify the clinical benefit of isaralgagene Civapec or support FDA approval, and that the patients withdrawn from ERT will remain off ERT; All forward-looking statements about Sangamo's future plans and expectations, including Sangamo's development plans for its product candidates, are subject to Sangamo's ability to secure adequate additional funding. There can be no assurance that Sangamo and its current or potential future partners.Major Estimate Revision • Nov 14Consensus revenue estimates fall by 37%The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from US$72.3m to US$45.6m. Forecast losses increased from -US$0.291 to -US$0.397 per share. Biotechs industry in the US expected to see average net income decline 9.7% next year. Consensus price target of US$3.25 unchanged from last update. Share price fell 2.5% to US$0.45 over the past week.ナラティブの更新 • Nov 08SGMO: FDA Approval Path Will Drive Bullish Outlook Into 2026Analysts have lowered their price target for Sangamo Therapeutics from $5 to $1. They cited a cautious outlook, pending greater clarity on a Fabry collaboration and updated guidance following the company's latest quarterly report.Price Target Changed • Nov 07Price target decreased by 21% to US$3.25Down from US$4.10, the current price target is an average from 5 analysts. New target price is 589% above last closing price of US$0.47. Stock is down 84% over the past year. The company is forecast to post a net loss per share of US$0.42 next year compared to a net loss per share of US$0.49 last year.Reported Earnings • Nov 06Third quarter 2025 earnings released: US$0.12 loss per share (vs US$0.045 profit in 3Q 2024)Third quarter 2025 results: US$0.12 loss per share (down from US$0.045 profit in 3Q 2024). Revenue: US$581.0k (down 99% from 3Q 2024). Net loss: US$34.9m (down 472% from profit in 3Q 2024). Revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.お知らせ • Oct 31Sangamo Therapeutics, Inc. to Report Q3, 2025 Results on Nov 06, 2025Sangamo Therapeutics, Inc. announced that they will report Q3, 2025 results at 9:30 AM, US Eastern Standard Time on Nov 06, 2025お知らせ • Oct 30Nasdaq Grants 180 Day Extension to Sangamo Therapeutics, Inc. to Regain ComplianceOn October 29, 2025, Sangamo Therapeutics, Inc. (the Company") received a letter (the Extension Notice") from The Nasdaq Stock Market LLC (Nasdaq") advising that the Company has been granted a 180-day extension, or until April 27, 2026, to regain compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Requirement"), in accordance with Nasdaq Listing Rule 5810(c)(3)(A). If at any time prior to April 27, 2026, the bid price of the Company's common stock, par value $0.01 per share (Common Stock"), closes at $1.00 per share or more for a minimum of 10 consecutive trading days, the Company will regain compliance with the Minimum Bid Price Requirement. The Extension Notice has no immediate effect on the listing of the Common Stock on The Nasdaq Capital Market and does not affect the Company's reporting requirements with the Securities and Exchange Commission (SEC"). As previously disclosed on the Current Report on Form 8-K filed with the SEC on May 5, 2025, the Company received a letter on April 30, 2025 from the Listing Qualifications Staff of Nasdaq indicating that, based upon the closing bid price of the Common Stock, for the preceding 30 consecutive business days, the Company was not in compliance with the Minimum Bid Price Requirement. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided 180 days, or until October 27, 2025, to regain compliance with the Minimum Bid Price Requirement. The Company intends to cure the Minimum Bid Price Requirement by April 27, 2026, however if the Company does not regain compliance with the Minimum Bid Price Requirement during this period, the Company expects that Nasdaq will provide written notification to the Company that its Common Stock will be delisted. At that time, the Company may appeal the delisting determination to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq listing rules. However, there can be no assurance that, if the Company does appeal the delisting determination by Nasdaq to the hearings panel, that such appeal would be successful. There can be no assurance that the Company will regain compliance with the Minimum Bid Price Requirement during the additional 180-day compliance period or maintain compliance with any other Nasdaq listing requirement.分析記事 • Oct 07There's No Escaping Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Muted Revenues Despite A 28% Share Price RiseSangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares have continued their recent momentum with a 28% gain in the last...分析記事 • Sep 23Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Are In A Position To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...ナラティブの更新 • Sep 21FDA Approval In 2026 Will Extend Fabry Gene Therapy ProspectsThe sharp increase in Sangamo Therapeutics' consensus analyst price target is primarily driven by a significantly higher future P/E expectation, indicating greater anticipated earnings growth or improved sentiment, with the fair value rising from $2.62 to $4.10. What's in the News CFO Prathyusha Duraibabu resigned, effective October 1, to join a private AI company; no disagreements cited in her departure.ナラティブの更新 • Sep 06FDA Approval In 2026 Will Extend Fabry Gene Therapy ProspectsSangamo Therapeutics' fair value has been revised downward, primarily reflecting meaningful declines in both its forward P/E multiple and net profit margin, resulting in a lower consensus price target of $2.62. What's in the News Sangamo presented detailed data from the registrational Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920), its investigational gene therapy for adults with Fabry disease, showing a positive mean annualized eGFR slope of 1.965 mL/min/1.73m2/year in all patients followed at least 12 months.お知らせ • Sep 04Sangamo Therapeutics, Inc. Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025Sangamo Therapeutics, Inc. announced detailed data from the registrational Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned investigational gene therapy for the treatment of adults with Fabry disease. These data were presented at the International Congress of Inborn Errors of Metabolism 2025 (ICIEM2025) in Kyoto, Japan, on September 4, 2025, in a poster presentation. Updated Phase 1/2 STAAR Study Results (as of April 10, 2025 cut-off date) Efficacy (32 dosed patients followed at least 12 months); A positive mean annualized eGFR slope of 1.965 mL/min/1.73m2/year (95% confidence interval (CI): -0.153, 4.083) at 52-we weeks was observed across all 32 dosed patients. Isaralgagene civapARvovec has been granted Orphan Drug, Fast Track and RMAT designations from the FDA, Orphan Medicinal Product designation and PRIME eligibility from the European Medicines Agency and Innovative Licensing and Access Pathway from U.K. Medicines and Healthcare products Regulatory Agency. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to Sangamo's lack of capital resources and need for substantial additional funding to execute its operating plan and to continue to operate as a going concern, including the risk that Sangamo will be unable to obtain substantial additional funding on acceptable terms or at all or collaboration partners necessary to advance its preclinical and clinical programs, in particular for its Fabry disease program and to otherwise operate as a going concern, in which case Sangamo may be required to cease operations entirely, liquidate all or a portion of its assets and/or seek protection under the U.S. Bankruptcy Code; the uncertain timing and unpredictable nature of clinical trial results, including the risk that the therapeutic effects observed in the latest clinical data from the Phase 1/2 STAAR trial will not validate the safety and efficacy of isaralgagene civapearvovec, including that the 104-week data from such study will not verify the clinical benefit of isaralgagene Civaparvovec or support FDA approval, and that the patients withdrawn from ERT will remain off ERT; the effects of macroeconomic factors or financial challenges, including as a result of the ongoing overseas conflicts, tariffs, geopolitical instability, inflation and fluctuations in interest rates, on the global business environment, healthcare systems and business and operations of Sangamo and its collaborators; the research and development process; the unpredictable regulatory approval process for product candidates across multiple regulatory authorities; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results, including the results of any regulatory trial of Sangamo's product candidates; the potential for technological developments that obviate technologies used by Sangamo; All forward-looking statements about Sangamo's future plans and expectations, including Sangamo's development plans for its product candidates, are subject to Sangamo's development plans for the treatment of adults withFabry disease.New Risk • Aug 11New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 45% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$36m free cash flow). Shareholders have been substantially diluted in the past year (45% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$1.6m net loss in 3 years). Share price has been volatile over the past 3 months (16% average weekly change).Reported Earnings • Aug 10Second quarter 2025 earnings: EPS and revenues miss analyst expectationsSecond quarter 2025 results: US$0.078 loss per share (improved from US$0.17 loss in 2Q 2024). Revenue: US$18.3m (up US$18.0m from 2Q 2024). Net loss: US$20.0m (loss narrowed 43% from 2Q 2024). Revenue missed analyst estimates by 42%. Earnings per share (EPS) also missed analyst estimates by 100%. Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings.お知らせ • Aug 01Sangamo Therapeutics, Inc. to Report Q2, 2025 Results on Aug 07, 2025Sangamo Therapeutics, Inc. announced that they will report Q2, 2025 results After-Market on Aug 07, 2025分析記事 • Jul 24Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Price Is Right But Growth Is Lacking After Shares Rocket 26%Those holding Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares would be relieved that the share price has rebounded...New Risk • May 15New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$98.4m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (19% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$68m net loss in 3 years). Market cap is less than US$100m (US$98.4m market cap).Major Estimate Revision • May 14Consensus revenue estimates fall by 54%The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from US$62.2m to US$28.7m. Forecast losses increased from -US$0.274 to -US$0.44 per share. Biotechs industry in the US expected to see average net income decline 13% next year. Consensus price target down from US$5.00 to US$4.10. Share price fell 33% to US$0.44 over the past week.New Risk • May 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$69m net loss in 3 years).Price Target Changed • May 13Price target decreased by 21% to US$4.10Down from US$5.17, the current price target is an average from 5 analysts. New target price is 791% above last closing price of US$0.46. Stock is down 19% over the past year. The company is forecast to post a net loss per share of US$0.42 next year compared to a net loss per share of US$0.49 last year.お知らせ • May 13Sangamo Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $22.972713 million.Sangamo Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $22.972713 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 12,235,000 Price\Range: $0.5 Discount Per Security: $0.03 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 34,398,393 Price\Range: $0.49 Discount Per Security: $0.0294お知らせ • May 07+ 1 more updateSangamo Therapeutics, Inc. to Report Q1, 2025 Results on May 12, 2025Sangamo Therapeutics, Inc. announced that they will report Q1, 2025 results After-Market on May 12, 2025お知らせ • May 06Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry DiseaseSangamo Therapeutics announced that all dosed patients have passed one-year milestone required by U.S. Food and Drug Administration (FDA) for Accelerated Approval regulatory pathway for ST-920. Preliminary analysis of clinical data collected as of this 52-week milestone date across all 32 dosed patients indicates that the mean eGFR slope continued to remain positive, following the last clinical update at the WORLDSymposium in February 2025, with a data cutoff date of September 12, 2024. Furthermore, in April 2025, Sangamo held a productive Type B meeting with the FDA, providing Sangamo with a clear CMC pathway to a planned BLA submission in the first quarter of 2026, including clarity on plans for process validation, path to commercial specifications and the commercial launch manufacturing site.お知らせ • May 01Sangamo Therapeutics, Inc., Annual General Meeting, Jun 12, 2025Sangamo Therapeutics, Inc., Annual General Meeting, Jun 12, 2025. Location: meetnow.global/murlfcm, United Statesお知らせ • Apr 29Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)Sangamo Therapeutics, Inc. announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted nine Sangamo abstracts for presentation at the 28th ASGCT Annual Meeting being held May 13-17, 2025, in-person in New Orleans, LA and in a virtual format. Presentations will highlight the progression of Sangamo’s neurology pipeline, including advances in zinc finger epigenetic regulation, the latest innovations in capsid delivery engineering, and developments in modular integrase technology. Data presentations at the ASGCT Annual Meeting include three oral presentations that detail Sangamo’s advances in the application of zinc finger repressors (ZFRs) as a novel class of epigenetic regulation for neurological disease targets. Two presentations – including one taking place in the Presidential Symposium – showcase how Sangamo is combining its ZFR targeting the prion gene with STAC-BBB, its intravenously administered neurotropic capsid, for the treatment of prion disease, a fatal and incurable neurodegenerative disease. These presentations describe the profound survival benefits of the treatment in disease mouse models, and the sustained, brain-wide suppression of prion protein expression in both mouse and nonhuman primate models, supporting its potential as a one-time therapeutic approach for prion disease. The third presentation focuses on the advancement of ST-503, a ZFR targeting the gene encoding Nav1.7, for the treatment of intractable, chronic neuropathic pain following intrathecal delivery. Additional poster presentations at the ASGCT Annual Meeting will showcase advances in novel adeno-associated virus (AAV) capsid engineering and manufacturing for central nervous system (CNS) delivery. Topics range from second-generation STAC-BBB variants and receptor-targeted AAVs, to innovations in manufacturing and quality control, including strategies to enhance yield, purity, and stability, and improve analytical assessment of AAV products. Sangamo will also present updated data from its protein-guided MINT platform as an approach to enable engineering of large gene-sized pieces of DNA. Collectively, these abstracts highlight the versatility, durability, and translational potential of ZFR-based gene regulation across diverse neurological applications.New Risk • Apr 07New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$67m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-US$67m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$71m net loss in 3 years). Share price has been volatile over the past 3 months (14% average weekly change).新しいナラティブ • Apr 01Neurology IND And Fabry Agreements Will Transform Treatment Strategic partnerships and collaborations position Sangamo as a key player, enhancing revenue potential through non-dilutive capital and licensing agreements. Reported Earnings • Mar 18Full year 2024 earnings: EPS and revenues miss analyst expectationsFull year 2024 results: US$0.49 loss per share (improved from US$1.48 loss in FY 2023). Revenue: US$57.8m (down 67% from FY 2023). Net loss: US$97.9m (loss narrowed 62% from FY 2023). Products in clinical trials Phase I: 1 Revenue missed analyst estimates by 6.8%. Earnings per share (EPS) also missed analyst estimates by 4.9%. Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.お知らせ • Mar 07Sangamo Therapeutics, Inc. to Report Q4, 2024 Results on Mar 17, 2025Sangamo Therapeutics, Inc. announced that they will report Q4, 2024 results After-Market on Mar 17, 2025分析記事 • Mar 04Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Looks Inexpensive After Falling 25% But Perhaps Not Attractive EnoughTo the annoyance of some shareholders, Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares are down a considerable 25% in...お知らせ • Feb 06Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety ProfileSangamo Therapeutics, Inc. announced updated data from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease. Updated Phase 1/2 STAAR Study Results (as of the September 12, 2024 cut-off date) Safety (all dosed patients): Isaralgagene civapARvovec continued to be generally well-tolerated, with the majority of adverse events being grade 1-2 in nature. Enrollment and dosing are complete in the Phase 1/2 STAar study. In October 2024, Sangamo announced that the FDA had provided a clear regulatory pathway to Accelerated Approval for isaralgagene civAParvovec using data from ongoing Phase 1/2 STAAR trial study, avoiding the requirement for an additional registrational study and accelerating estimated time to potential approval by approximately three years. The FDA agreed in a Type B interaction that data from the ongoing Phase 1/2 STA AR study can serve as the primary basis for approval under the Accelerated Approval Program, using eGFR slope at 52 weeks across all patients as an intermediate clinical endpoint. The 52-week eGFR slope data from all enrolled patients in the Phase 1/2STAR study will be available in the first half of 2025. Sangamo believes that its zinc finger epigenetic regulators are ideally suited to potentially address devastating neurological disorders and that its capsid discovery platform can expand delivery beyond currently available intrathecal delivery capsids, including the central nervous system. These forward-looking statements include, without limitation, statements relating to: the safety and efficacy and therapeutic potential of isaralgagene Civaparvovec, including the potential for it to be a one-time, durable treatment option for Fabry disease that can improve patient outcomes; the presentation of clinical data from the phase 1/2 STAAR study; the potential for isaralgagene CivAParvovec to qualify for the FDA's Accelerated Approval program, including the adequacy of data generated in the Phase 1/2 ST-920 study to support any such approval; expectations concerning the availability of additional data to support a potential BLA submission for isaralgagene civicaparvovec, and the timing of such submission; the potential to accelerate the expected timeline to approval of isaralgagene civapearvovec; Sangamo's plans to advance discussions with the FDA and the European Medicines Agency; Factors that could cause actual results to difference include, but are not limited to, risks and uncertainties related to Sangamo's lack of capital resources to obtain regulatory approval for and commercialize its product candidates in a timely manner or at all, including the ability to secure a collaboration partner for ST-920; the uncertain timing and unpredictable nature of clinical trial results, including the risk that the therapeutic effects observed in the latest preliminary clinical data from the Phase 1/2 STAAR study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene citizensaparvovec, a fully owned gene therapy product candidate for ST-920, a wholly owned gene therapy product candidate for Fabry disease.分析記事 • Dec 08Investors Don't See Light At End Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Tunnel And Push Stock Down 30%Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares have retraced a considerable 30% in the last month, reversing a fair...分析記事 • Nov 20Analysts Just Made A Massive Upgrade To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) ForecastsSangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shareholders will have a reason to smile today, with the analysts making...お知らせ • Nov 20Sangamo Therapeutics, Inc. Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic PainSangamo Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for its ST-503 program, an investigational epigenetic regulator for the treatment of intractable pain due to idiopathic small fiber neuropathy (iSFN), a type of chronic neuropathic pain. Neuropathic pain can be caused by a broad array of pathologies impacting the central or peripheral nervous systems, such as surgical trauma, spinal cord injury, nerve compression, neurological and infectious diseases, or metabolic and hereditary syndromes. ST-503 is not intended for sporadic or acute pain, but for chronic, intractable pain that completely dominates and often destroys the lives of patients over many years. The Phase 1/2 study will assess the safety and efficacy of ST-503 in addressing iSFN, a peripheral neuropathy that results in highly debilitating symptoms of burning, prickling, stabbing or “lightning-like” pain. iSFN has an estimated prevalence of at least 43,000 patients in the U.S., and more broadly, peripheral neuropathies are estimated to affect nearly 40 million Americans. Antidepressants, anticonvulsants, opioids and topical therapies are potential treatment options, although no long-lasting or curative therapies are currently available for iSFN patients, leading to a high unmet medical need for this patient population. A significant body of evidence implicates sodium channels in mediating the pathophysiology of neuropathic pain. ST-503 uses an adeno-associated virus (AAV) vector carrying an engineered zinc finger repressor (ZFR) to specifically target the human gene, SCN9A, that encodes the Nav1.7 sodium channel and is critical for pain signaling. Developing small molecules that specifically target Nav1.7 is challenging due to the high structural similarities between different sodium channels, making it difficult to achieve selectivity and avoid off-target effects. By directly targeting the SCN9A gene, ST-503 was shown to selectively reduce the expression of Nav1.7 sodium channels in sensory neurons in animal models and significantly reduce pain hypersensitivity, following a single intrathecal administration of ST-503. Sangamo’s preclinical research has shown ST-503 to be well tolerated in nonhuman primates, with substantial Nav1.7 reduction observed with no off-target effects, demonstrating the promise of ST-503 as a potential therapy for chronic neuropathic pain, regardless of cause. Sangamo is preparing for the Phase 1/2 clinical study to assess the safety, tolerability and preliminary efficacy of a one-time dose of ST-503, administered intrathecally to patients with intractable pain due to iSFN, and plans to initiate patient enrollment in mid-2025. Sangamo believes that if this study is successful, the development of ST-503 could be broadened to patient populations suffering from other types of chronic neuropathic pain.Reported Earnings • Nov 14Third quarter 2024 earnings: EPS and revenues exceed analyst expectationsThird quarter 2024 results: EPS: US$0.051 (up from US$0.59 loss in 3Q 2023). Revenue: US$49.4m (up 426% from 3Q 2023). Net income: US$10.7m (up US$114.8m from 3Q 2023). Profit margin: 22% (up from net loss in 3Q 2023). The move to profitability was primarily driven by higher revenue. Revenue exceeded analyst estimates by 97%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 39% per year, which means it is performing significantly worse than earnings.New Risk • Nov 14New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.07% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$179m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings are forecast to decline by an average of 0.07% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$26m net loss in 3 years). Shareholders have been diluted in the past year (17% increase in shares outstanding).Major Estimate Revision • Nov 07Consensus revenue estimates fall by 17%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$41.2m to US$34.1m. Forecast losses increased from -US$0.53 to -US$0.554 per share. Biotechs industry in the US expected to see average net income decline 14% next year. Consensus price target up from US$3.80 to US$4.80. Share price rose 65% to US$2.81 over the past week.お知らせ • Nov 05Sangamo Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024Sangamo Therapeutics, Inc. announced that they will report Q3, 2024 results After-Market on Nov 12, 2024分析記事 • Oct 23What Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 26% Share Price Gain Is Not Telling YouSangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares have continued their recent momentum with a 26% gain in the last...Seeking Alpha • Oct 21Sangamo Follow-Up: Giro-Vec And STAC-BBB? Check. Isa-Vec... Trifecta Soon?Summary Sangamo Therapeutics, Inc.'s stock surged after positive updates on two lead assets, giro-vec and STAC-BBB, with potential for significant milestone payments and partnerships. The upcoming isa-vec deal could be transformative, potentially securing Sangamo's financial stability and pushing its valuation towards $1 billion. Despite recent gains, high volatility and financial risks make SGMO a speculative investment, suitable only for risk-tolerant investors. Key risks include potential setbacks in giro-vec and isa-vec developments, which could impact Sangamo's cash flow and overall valuation. Read the full article on Seeking AlphaMajor Estimate Revision • Aug 23Consensus revenue estimates increase by 32%The consensus outlook for revenues in fiscal year 2024 has improved. 2024 revenue forecast increased from US$31.3m to US$41.2m. Forecast losses expected to reduce from -US$0.483 to -US$0.461 per share. Biotechs industry in the US expected to see average net income decline 14% next year. Consensus price target of US$3.80 unchanged from last update. Share price fell 2.5% to US$0.86 over the past week.Reported Earnings • Aug 07Second quarter 2024 earnings: EPS and revenues miss analyst expectationsSecond quarter 2024 results: US$0.18 loss per share (improved from US$0.66 loss in 2Q 2023). Revenue: US$356.0k (down 95% from 2Q 2023). Net loss: US$36.1m (loss narrowed 68% from 2Q 2023). Revenue missed analyst estimates by 96%. Earnings per share (EPS) also missed analyst estimates by 23%. Revenue is forecast to grow 54% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 56% per year, which means it is performing significantly worse than earnings.分析記事 • Aug 03There's Reason For Concern Over Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Massive 171% Price JumpSangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shareholders would be excited to see that the share price has had a great...お知らせ • Jul 31Sangamo Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024Sangamo Therapeutics, Inc. announced that they will report Q2, 2024 results After-Market on Aug 06, 2024New Risk • Jul 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$218m). Currently unprofitable and not forecast to become profitable over next 3 years (US$23m net loss in 3 years). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (US$83.3m market cap).Seeking Alpha • Jul 23Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The RemakingSummary Sangamo Therapeutics, Inc. is almost out of cash, and as such, at risk of bankruptcy. Therefore, investing in this company is not a good idea for most investors. 3 of its assets have updates coming over the next 1–6 months that could realistically bring in a combination of ~$1B of cash & milestones over the next 12–18 months. Due to its history of burning cash and not being able to get a drug approved yet, Sangamo Therapeutics's stock price closed Monday, 07/22/24 at $0.395/s or a valuation of ~$82M. Below, I will discuss why I think the company is going to make it and possibly deliver 5-10x over the next 6–12 months. Read the full article on Seeking Alpha分析記事 • Jun 19Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 35% Price DropUnfortunately for some shareholders, the Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) share price has dived 35% in the...分析記事 • May 29We Think Shareholders May Want To Consider A Review Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation PackageKey Insights Sangamo Therapeutics' Annual General Meeting to take place on 4th of June CEO Sandy Macrae's total...Major Estimate Revision • May 21Consensus EPS estimates fall by 10%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$42.8m to US$38.8m. Losses expected to increase from US$0.44 per share to US$0.48. Biotechs industry in the US expected to see average net income decline 11% next year. Consensus price target of US$3.50 unchanged from last update. Share price rose 5.2% to US$0.60 over the past week.分析記事 • May 14This Just In: Analysts Are Boosting Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Outlook for This YearShareholders in Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) may be thrilled to learn that the analysts have just...New Risk • May 13New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$218m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$218m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$56m net loss in 3 years). Shareholders have been diluted in the past year (21% increase in shares outstanding).Reported Earnings • May 10First quarter 2024 earnings released: US$0.27 loss per share (vs US$0.13 profit in 1Q 2023)First quarter 2024 results: US$0.27 loss per share (down from US$0.13 profit in 1Q 2023). Revenue: US$481.0k (down 100% from 1Q 2023). Net loss: US$49.1m (down 332% from profit in 1Q 2023). Revenue is forecast to grow 49% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.お知らせ • May 10Sangamo Therapeutics, Inc. Reports Impairment Charges for the First Quarter Ended March 31, 2024Sangamo Therapeutics, Inc. reported impairment charges for the first quarter ended March 31, 2024. For the quarter, the company reported impairment of long-lived assets of $4,349,000 compared to $20,433,000 a year ago.お知らせ • May 03Sangamo Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024Sangamo Therapeutics, Inc. announced that they will report Q1, 2024 results After-Market on May 09, 2024お知らせ • May 01Sangamo Therapeutics, Inc. Receives A Deficiency Notice from NasdaqOn April 24, 2024, Sangamo Therapeutics, Inc. (the Company") received a deficiency notice, or the Notice, from the Listing Qualifications Staff, or the Staff, of The Nasdaq Stock Market LLC, or Nasdaq, notifying the Company that, for the last 30 consecutive business days, the bid price of the Company's common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5450(a)(1). The Notice has no immediate effect on the listing of the Company's common stock on the Nasdaq Global Select Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until October 21, 2024, or the Compliance Date, to regain compliance with the minimum bid price requirement by having shares of the Company's common stock maintain a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days before the Compliance Date. If the Company's common stock does not achieve compliance by the Compliance Date, the Company may be eligible for an additional 180-day period to regain compliance. To qualify for the second compliance period, the Company would be required to transfer its listing to the Nasdaq Capital Market and meet the continued listing requirement for market value of publicly held shares and all other applicable initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice to Nasdaq of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. However, if it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible for the second compliance period, and the Company does not regain compliance by the Compliance Date, the Staff will provide written notification that the Company's common stock is subject to delisting. At that time, the Company may appeal the delisting determination to a hearings panel pursuant to the procedures set in the applicable Nasdaq listing rules. However, there can be no assurance that, if the Company receives a delisting notice and appeals the delisting determination by Nasdaq to the panel, such appeal would be successful. The Company intends to actively monitor the closing bid price of its common stock between now and the Compliance Date and, as appropriate, will evaluate available options to resolve the deficiency and regain compliance with the minimum bid price requirement.お知らせ • Apr 21Sangamo Therapeutics, Inc., Annual General Meeting, Jun 04, 2024Sangamo Therapeutics, Inc., Annual General Meeting, Jun 04, 2024, at 08:30 Pacific Standard Time. Agenda: To elect the nine nominees for director named in the proxy statement, or the Proxy Statement, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2025 and until their successors are duly elected and qualified; to approve, on an advisory basis, the compensation of named executive officers, or NEOs; to approve the amendment and restatement of the Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan, or the 2018 Plan, to, among other things, increase the aggregate number of shares of common stock reserved for issuance under the 2018 Plan by 11,000,000 shares; to ratify the appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2024; and to transact such other business as may properly come before the meeting.New Risk • Apr 19New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$98.8m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (25% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$88m net loss in 3 years). Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (US$98.8m market cap).お知らせ • Mar 25Sangamo Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $24 million.Sangamo Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $24 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 24,761,905 Price\Range: $0.84 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 3,809,523 Price\Range: $0.84 Transaction Features: Registered Direct Offering分析記事 • Mar 23Little Excitement Around Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues As Shares Take 36% PoundingSangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares have retraced a considerable 36% in the last month, reversing a fair...お知らせ • Mar 22Sangamo Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $24 million.Sangamo Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $24 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 24,761,905 Price\Range: $0.84 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 3,809,523 Price\Range: $0.84 Transaction Features: Registered Direct OfferingMajor Estimate Revision • Mar 20Consensus revenue estimates fall by 13%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$42.5m to US$36.9m. Forecast losses increased from -US$0.483 to -US$0.499 per share. Biotechs industry in the US expected to see average net income decline 8.2% next year. Consensus price target of US$3.50 unchanged from last update. Share price fell 11% to US$0.77 over the past week.分析記事 • Mar 16Analysts Have Just Cut Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Estimates By 24%Today is shaping up negative for Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shareholders, with the analysts delivering...お知らせ • Mar 14Sangamo Therapeutics, Inc. Reports Impairment Results for the Fourth Quarter Ended December 31, 2023Sangamo Therapeutics, Inc. reported impairment results for the fourth quarter ended December 31, 2023. For the quarter, the company reported Impairment of long-lived assets of $0.3 million.Reported Earnings • Mar 13Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: US$1.48 loss per share (further deteriorated from US$1.25 loss in FY 2022). Revenue: US$176.2m (up 58% from FY 2022). Net loss: US$257.8m (loss widened 34% from FY 2022). Revenue missed analyst estimates by 3.3%. Earnings per share (EPS) also missed analyst estimates by 6.9%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 60% per year, which means it is performing significantly worse than earnings.お知らせ • Mar 13+ 1 more updateSangamo Therapeutics, Inc. to Report Q4, 2023 Results on Mar 13, 2024Sangamo Therapeutics, Inc. announced that they will report Q4, 2023 results Pre-Market on Mar 13, 2024株主還元SGMOUS BiotechsUS 市場7D15.1%-1.6%-0.8%1Y-68.5%34.4%27.1%株主還元を見る業界別リターン: SGMO過去 1 年間で34.4 % の収益を上げたUS Biotechs業界を下回りました。リターン対市場: SGMOは、過去 1 年間で27.1 % のリターンを上げたUS市場を下回りました。価格変動Is SGMO's price volatile compared to industry and market?SGMO volatilitySGMO Average Weekly Movement25.5%Biotechs Industry Average Movement11.0%Market Average Movement7.2%10% most volatile stocks in US Market16.3%10% least volatile stocks in US Market3.2%安定した株価: SGMOの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: SGMOの 週次ボラティリティ は、過去 1 年間で18%から26%に増加しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト1995142Sandy Macraewww.sangamo.comSangamo Therapeutics, Inc.は臨床段階のゲノム医療企業であり、米国で重篤な疾患に苦しむ患者やその家族の生活を変革する医薬品に科学を転換することに注力している。同社の臨床段階にある製品候補は、ファブリー病、慢性神経障害性疼痛の小繊維神経障害、プリオン病の治療薬として第1/2相臨床試験中の遺伝子治療薬ST-920、腎移植を受ける患者を対象とした治験中の遺伝子改変細胞治療薬TX200の安全性と忍容性を評価する第1/2相臨床試験、遺伝子治療薬SB-525、ファブリー病、慢性神経障害性疼痛の小繊維神経障害、プリオン病の治療薬として第1/2相臨床試験中の遺伝子治療薬ST-920、腎移植を受ける患者を対象とした治験中の遺伝子改変細胞治療薬SB-525である。遺伝子治療製品候補であるSB-525は、中等症から重症の血友病Aの治療薬として第3相臨床試験中であり、giroctocogene fitelparvovecは、中等症から重症の血友病Aの成人男性を対象としたgiroctocogene fitelparvovec遺伝子治療の臨床的有効性と安全性を評価する第3相臨床試験である。サンガモ・セラピューティクス社は、ジェネンテック社、アステラス・ジーンセラピー社、イーライリリー・アンド・カンパニー社とのカプシドデリバリーライセンス契約、アレクシオン・ファーマシューティカルズ社（ALSおよび前頭側頭葉変性症）、武田薬品工業社（ハンチントン病）、およびコルテバ・アグリサイエンス社およびオープンモノクローナルテクノロジー社とのトランスジェニック動物の生産や細胞株工学を含む植物農業や研究試薬などの分野と協力的・戦略的パートナーシップを結んでいる。以前はサンガモ・バイオサイエンシズ社として知られていたが、2017年1月にサンガモ・セラピューティクス社に社名変更した。1995年に法人化され、カリフォルニア州リッチモンドに本社を置いている。もっと見るSangamo Therapeutics, Inc. 基礎のまとめSangamo Therapeutics の収益と売上を時価総額と比較するとどうか。SGMO 基礎統計学時価総額US$64.63m収益（TTM）-US$123.33m売上高(TTM)US$34.56m1.9xP/Sレシオ-0.5xPER（株価収益率SGMO は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計SGMO 損益計算書（TTM）収益US$34.56m売上原価US$112.67m売上総利益-US$78.11mその他の費用US$45.22m収益-US$123.33m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.30グロス・マージン-226.04%純利益率-356.89%有利子負債／自己資本比率0%SGMO の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 13:27終値2026/05/21 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Sangamo Therapeutics, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。16 アナリスト機関Gregory HarrisonBofA Global ResearchDouglas BuchananBrean Capital Historical (Janney Montgomery)John NewmanCitizens JMP Securities, LLC13 その他のアナリストを表示
お知らせ • May 12Sangamo Therapeutics, Inc. to Report Q1, 2026 Results on May 14, 2026Sangamo Therapeutics, Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 14, 2026
お知らせ • May 06Sangamo Therapeutics, Inc.(OTCPK:SGMO) dropped from NASDAQ Composite IndexSangamo Therapeutics, Inc. has been dropped from the NASDAQ Composite Index.
お知らせ • Apr 30+ 1 more updateSangamo Therapeutics, Inc. Presents Pipeline And Technology Advances At The American Society Of Gene & Cell Therapy Annual MeetingSangamo Therapeutics, Inc. announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted three Sangamo abstracts for presentation at the 29th ASGCT Annual Meeting being held May 11-15, 2026, in-person in Boston, MA and in a virtual format. Presentations will highlight the progression of Sangamo’s neurology pipeline, including advances in zinc finger epigenetic regulation and developments in modular integrase technology. Presentations at the ASGCT Annual Meeting include two posters detailing Sangamo’s advances in the application of zinc finger repressors (ZFRs) as a novel class of epigenetic regulation for neurological disease targets – specifically in chronic neuropathic pain and in prion disease. A platform presentation will showcase updated data from Sangamo’s protein-guided MINT platform as an approach to integrate large sequences of DNA into the genome to potentially treat, with a single medicine, many different patients who have unique mutations in the same gene. The MINT platform could be deployed internally for neurology-focused indications, and could provide potential new collaboration opportunities, both for human disease and in agricultural biotech settings. Neurology Epigenetic Regulation: ST-503 nonclinical safety studies evaluating zinc finger repressors regulating the expression of the Nav1.7 gene for treatment of small fiber neuropathy. Abstract No. 1309. Poster Presentation – Tuesday, May 12, 5:00-6:30pm EDT. Single-cell characterization of ST-506, a BBB-penetrant epigenetic repressor of Prion protein expression, in the nonhuman primate brain. Abstract No. 1469. Poster Presentation – Tuesday, May 12, 5:00-6:30pm EDT. Next-Generation Genome Engineering: Zinc finger fusions and synthetic DNA donor engineering improve the performance of reprogrammed modular integrases at the TRAC locus. Abstract No. 105. Oral Presentation – Tuesday, May 12, 4:00-4:15pm EDT. Session Name: Next-generation platforms for precise therapeutic genome editing and integration.
ナラティブの更新 • Apr 20SGMO: Fabry Filing Progress Will Offset Going Concern And Liquidity FearsAnalysts have updated their price target on Sangamo Therapeutics to reflect revised assumptions for the discount rate, revenue growth, profit margin and future P/E. The new fair value estimate remains at $1.00, in line with the prior $1.00 target.
Major Estimate Revision • Apr 07Consensus revenue estimates increase by 22%The consensus outlook for revenues in fiscal year 2026 has improved. 2026 revenue forecast increased from US$55.4m to US$67.6m. Forecast losses expected to reduce from -US$0.245 to -US$0.153 per share. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target broadly unchanged at US$3.75. Share price rose 3.7% to US$0.26 over the past week.
ナラティブの更新 • Apr 06SGMO: Fabry Gene Therapy Filing And Diagnostic Will Drive Future UpsideAnalysts have trimmed their price target on Sangamo Therapeutics from $1.25 to $1.00, citing updated assumptions for revenue growth, profit margins and future P/E that have reset expectations for the stock. What's in the News Sangamo reported unaudited impairment charges on long lived assets of US$13,235,000 for the fourth quarter ended December 31, 2025, which affects reported earnings quality for that period (Key Developments).
お知らせ • May 12Sangamo Therapeutics, Inc. to Report Q1, 2026 Results on May 14, 2026Sangamo Therapeutics, Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 14, 2026
お知らせ • May 06Sangamo Therapeutics, Inc.(OTCPK:SGMO) dropped from NASDAQ Composite IndexSangamo Therapeutics, Inc. has been dropped from the NASDAQ Composite Index.
お知らせ • Apr 30+ 1 more updateSangamo Therapeutics, Inc. Presents Pipeline And Technology Advances At The American Society Of Gene & Cell Therapy Annual MeetingSangamo Therapeutics, Inc. announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted three Sangamo abstracts for presentation at the 29th ASGCT Annual Meeting being held May 11-15, 2026, in-person in Boston, MA and in a virtual format. Presentations will highlight the progression of Sangamo’s neurology pipeline, including advances in zinc finger epigenetic regulation and developments in modular integrase technology. Presentations at the ASGCT Annual Meeting include two posters detailing Sangamo’s advances in the application of zinc finger repressors (ZFRs) as a novel class of epigenetic regulation for neurological disease targets – specifically in chronic neuropathic pain and in prion disease. A platform presentation will showcase updated data from Sangamo’s protein-guided MINT platform as an approach to integrate large sequences of DNA into the genome to potentially treat, with a single medicine, many different patients who have unique mutations in the same gene. The MINT platform could be deployed internally for neurology-focused indications, and could provide potential new collaboration opportunities, both for human disease and in agricultural biotech settings. Neurology Epigenetic Regulation: ST-503 nonclinical safety studies evaluating zinc finger repressors regulating the expression of the Nav1.7 gene for treatment of small fiber neuropathy. Abstract No. 1309. Poster Presentation – Tuesday, May 12, 5:00-6:30pm EDT. Single-cell characterization of ST-506, a BBB-penetrant epigenetic repressor of Prion protein expression, in the nonhuman primate brain. Abstract No. 1469. Poster Presentation – Tuesday, May 12, 5:00-6:30pm EDT. Next-Generation Genome Engineering: Zinc finger fusions and synthetic DNA donor engineering improve the performance of reprogrammed modular integrases at the TRAC locus. Abstract No. 105. Oral Presentation – Tuesday, May 12, 4:00-4:15pm EDT. Session Name: Next-generation platforms for precise therapeutic genome editing and integration.
ナラティブの更新 • Apr 20SGMO: Fabry Filing Progress Will Offset Going Concern And Liquidity FearsAnalysts have updated their price target on Sangamo Therapeutics to reflect revised assumptions for the discount rate, revenue growth, profit margin and future P/E. The new fair value estimate remains at $1.00, in line with the prior $1.00 target.
Major Estimate Revision • Apr 07Consensus revenue estimates increase by 22%The consensus outlook for revenues in fiscal year 2026 has improved. 2026 revenue forecast increased from US$55.4m to US$67.6m. Forecast losses expected to reduce from -US$0.245 to -US$0.153 per share. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target broadly unchanged at US$3.75. Share price rose 3.7% to US$0.26 over the past week.
ナラティブの更新 • Apr 06SGMO: Fabry Gene Therapy Filing And Diagnostic Will Drive Future UpsideAnalysts have trimmed their price target on Sangamo Therapeutics from $1.25 to $1.00, citing updated assumptions for revenue growth, profit margins and future P/E that have reset expectations for the stock. What's in the News Sangamo reported unaudited impairment charges on long lived assets of US$13,235,000 for the fourth quarter ended December 31, 2025, which affects reported earnings quality for that period (Key Developments).
お知らせ • Apr 01Sangamo Therapeutics, Inc. Reports Unaudited consolidated Impairment Charges for the Fourth Quarter Ended December 31, 2025Sangamo Therapeutics, Inc. reported Unaudited consolidated impairment charges for the fourth quarter ended December 31, 2025. For the period, the company reported impairment of long-lived assets of $13,235,000.
Reported Earnings • Mar 31Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: US$0.44 loss per share. Revenue: US$39.6m (down 32% from FY 2024). Net loss: US$122.9m (loss widened 26% from FY 2024). Revenue missed analyst estimates by 40%. Earnings per share (EPS) also missed analyst estimates by 42%. Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.
ナラティブの更新 • Mar 22SGMO: Fabry Gene Therapy Filing And Kidney Endpoint Will Drive UpsideAnalysts have adjusted their price target on Sangamo Therapeutics to $1.25, with the change based on updated views on discount rate, revenue growth, profit margin, and future P/E assumptions, even though the fair value estimate itself remains $1.25. What's in the News Sangamo started a rolling submission of a Biologics License Application to the FDA for isaralgagene civaparvovec (ST-920), an investigational one time gene therapy for adults with Fabry disease, and has submitted the preclinical and clinical modules for review (Key Developments).
お知らせ • Mar 20Sangamo Therapeutics, Inc. to Report Q4, 2025 Results on Mar 30, 2026Sangamo Therapeutics, Inc. announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on Mar 30, 2026
お知らせ • Mar 10Sangamo Therapeutics, Inc. Advances Rolling Submission Of BLA To U.S. FDA For ST-920 In Fabry DiseaseSangamo Therapeutics, Inc. announced advancement of the rolling submission of a BLA to the FDA seeking accelerated approval of isaralgagene civaparvovec, or ST-920, a wholly owned investigational gene therapy for the treatment of adults with Fabry disease. Following initiation of the rolling submission in December 2025, Sangamo has now submitted the preclinical and clinical modules to the FDA for review. Rolling submission allows for completed modules of the BLA to be submitted and reviewed by the FDA on an ongoing basis rather than waiting for the entire BLA to be submitted at once. In addition, the antibody assay companion diagnostic, which is designed to screen patients for eligibility with isaralgagene civaparvovec, has been submitted to, and accepted by, the FDA’s Center for Devices and Radiological Health (CDRH) seeking Premarket Approval (PMA). The STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which the FDA has agreed will serve as endpoint to support accelerated approval. These data were presented via four platform presentations and in poster presentations at the recent 22nd Annual WORLDSymposium™. These data are available on Sangamo’s website on the Presentations page. The Phase 1/2 STAAR study is a global open-label, single-dose, dose-ranging, multicenter clinical study designed to evaluate isaralgagene civaparvovec, or ST-920, a gene therapy product candidate in patients with Fabry disease. Isaralgagene civaparvovec requires a one-time infusion without preconditioning. Isaralgagene civaparvovec has been granted Orphan Drug, Fast Track and RMAT designations from the FDA, Orphan Medicinal Product designation and PRIME eligibility from the European Medicines Agency and Innovative Licensing and Access Pathway from U.K. Medicines and Healthcare products Regulatory Agency. Fabry disease is a lysosomal storage disorder caused by mutations in the galactosidase alpha gene (GLA), which leads to deficient alpha-galactosidase A (a-Gal A) enzyme activity, which is necessary for metabolizing globotriaosylceramide (Gb3). The buildup of Gb3 in the cells can cause serious damage to vital organs, including the kidney, heart, nerves, eyes, gut and skin. Symptoms of Fabry disease can include decreased or absent sweat production, heat intolerance, angiokeratoma (skin blemishes), vision problems, kidney disease, heart failure, gastrointestinal disturbance, mood disorders, neuropathic pain and tingling in the extremities.
ナラティブの更新 • Mar 08SGMO: Accelerated Approval Pathway On Kidney Data Will Drive Bullish UpsideAnalysts have set their price target for Sangamo Therapeutics at $1.25, based on updated assumptions for discount rate, revenue growth, profit margin, and future P/E, while the fair value estimate remains unchanged at $1.25. What's in the News Sangamo reported detailed data from the registrational Phase 1/2 STAAR study of its gene therapy candidate isaralgagene civaparvovec (ST 920) for Fabry disease.
ナラティブの更新 • Feb 22SGMO: Accelerated Approval On Kidney Function Data Will Drive Bullish ThesisAnalysts have maintained their average price target for Sangamo Therapeutics at $1.25. This reflects minor adjustments to their models, including slightly different assumptions for discount rate, revenue growth, profit margin, and forward P/E, rather than a change in their overall view.
ナラティブの更新 • Feb 07SGMO: Accelerated Approval Using EGFR Slope Will Support Bullish OutlookAnalysts have nudged their fair value estimate for Sangamo Therapeutics higher to $1.25 from $1.00, citing updated assumptions around revenue growth, profit margins, discount rates and a higher future P/E multiple. What's in the News Sangamo Therapeutics completed a follow on equity offering totaling approximately US$24.8 million, issuing 35,190,292 shares of common stock at US$0.4719 per share and 17,787,033 pre funded warrants at US$0.4619 per warrant (Key Developments).
お知らせ • Feb 04Sangamo Therapeutics, Inc. Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium 2026Sangamo Therapeutics, Inc. announced detailed data from the registrational Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease. These data will be presented via four platform presentations and in poster presentations at the 22nd Annual WORLDSymposium taking place in San Diego, CA, February 2-6, 2026.Sangamo believes that the totality of data from the registrational STAAR study demonstrates the potential of isaralgagene civaparvovec as a one-time, well-tolerated and durable gene therapy treatment option for Fabry disease to provide meaningful, multi-organ clinical benefits that could fundamentally shift the Fabry treatment paradigm. As of the April 10, 2025 data cut-off date, a positive mean annualized eGFR slope of 1.965 mL/min/1.73m/year (95% confidence interval (CI): -0.153, 4.083) at 52-weeks was observed across all 32 dosed patients, indicating an improvement in renal function. Furthermore, a mean annualized eGFR slope of 1.747 mL/min/1.73m/year (95% CI: -0.106, 3.601) was observed for the 19 patients who had achieved 104-weeks of follow-up. Stable cardiac function was observed over one year, including consistent cardiac structural stability across clinical and demographic subgroups. Durability of effect was demonstrated with elevated expression of alpha-galactosidase A (a-Gal A) activity maintained for up to 4.5 years for the longest treated patient, alongside statistically significant Quality of Life improvements and other clinical benefits. Isaralgagene civaparvovec demonstrated a favorable safety and tolerability profile in the study, without the requirement for preconditioning. The Phase 1/2 STAAR Study is complete, and 32 patients have successfully rolled into the long-term follow-up study. The FDA has provided a clear regulatory pathway to Accelerated Approval for isaralgagene Civaparvovec, agree that data from the ongoing Phase 1/2 STAAR trial can serve as the primary basis for approval under the Accelerated Approval Program, using mean annualized eGFR slope at 52 weeks as an intermediate clinical endpoint. In December 2025, Sangamo initiated a rolling submission of a BLA to the FDA seeking approval of isaralgagene civAParvovec under an Accelerated Approval pathway.
お知らせ • Feb 03Sangamo Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $24.822129 million.Sangamo Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $24.822129 million. Security Name: common Stock Security Type: Common Stock Securities Offered: 35,190,292 Price\Range: $0.4719 Discount Per Security: $0.0283 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 17,787,033 Price\Range: $0.4619 Discount Per Security: $0.0277
分析記事 • Feb 03Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Share Price Boosted 29% But Its Business Prospects Need A Lift TooSangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares have had a really impressive month, gaining 29% after a shaky period...
New Risk • Jan 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$76m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Shareholders have been substantially diluted in the past year (61% increase in shares outstanding).
ナラティブの更新 • Jan 23SGMO: Accelerated Approval Pathway Will Drive Upside Despite Downgrade Through 2026Narrative Update Analysts have cut their price target on Sangamo Therapeutics from US$5 to US$1, citing the recent downgrade to Equal Weight and a wait for more clarity on a potential Fabry deal, despite the FDA reaffirming an accelerated approval path and the company extending its cash runway into Q1 2026. Analyst Commentary Recent research paints a mixed picture for Sangamo Therapeutics, with the lower price target and rating downgrade balanced against some supportive clinical and balance sheet signals.
ナラティブの更新 • Jan 09SGMO: Accelerated Approval Path Using EGFR Slope Will Drive Future UpsideAnalysts have trimmed their 12 month price target on Sangamo Therapeutics to US$1 from US$5, citing a wait and see stance on Fabry deal clarity and the current cash runway into Q1 2026, despite the reaffirmed accelerated approval path using eGFR slope. Analyst Commentary Bearish analysts are signaling a more cautious stance on Sangamo Therapeutics after the recent Q3 update, with the sharp cut in the 12 month price target standing out as a key marker of reduced confidence.
ナラティブの更新 • Dec 25SGMO: Accelerated Approval Pathway And Extended Runway Will Support Upside Through 2026Analysts have modestly reduced their price target on Sangamo Therapeutics to $1 from $5, citing a more cautious stance as they await greater clarity on potential Fabry partnership developments, despite the extended cash runway and reaffirmed accelerated approval pathway. Analyst Commentary Analysts note that the downgrade and lower price target reflect a shift toward a more balanced risk reward profile, with recent catalysts prompting both supportive and cautious views on Sangamo Therapeutics.
お知らせ • Dec 18Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry DiseaseSangamo Therapeutics, Inc. has initiated a rolling submission of a BLA to the FDA seeking accelerated approval of isaralgagene civaparvovec, or ST-920, a wholly owned investigational gene therapy for the treatment of adults with Fabry disease. Rolling submission allows for completed modules of the BLA to be submitted and reviewed by the FDA on an ongoing basis rather than waiting for the entire BLA to be submitted at once. Furthermore, the STAAR study demonstrated a positive mean annualized eGFR slope at 52-we weeks across all dosed patients in the study, which the FDA has agreed will serve as endpoint to support accelerated approval. Isaralgagene civapARvovec has been granted Orphan Drug, Fast Track and RMAT designations from the FDA, Orphan Medicinal Product designation and PRIME eligibility from the European Medicines Agency and Innovative Licensing and Access Pathway from U.K. Medicines and Healthcare products Regulatory Agency. Sangamo expects to complete submission of the BLA to the FDA under the accelerated approval pathway in the second quarter of 2026. Sangamo believes that its zinc finger epigenetic regulators are ideally suited to potentially address devastating neurological disorders and that its capsid discovery platform can expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system. These forward-looking statements include, without limitation, statements relating to: the safety and efficacy and therapeutic potential of isaralgagene Civaparvovec, including the potential for it to be a one-time, durable treatment option for Fabry disease to provide meaningful, multi-organ clinical benefits above current standards of care; the potential for isaralgagene civapearvovec to qualify for the FDA's accelerated approval program, including the adequacy of data generated in the Phase 1/2 STAAR study to support any such approval; expectations regarding the availability of additional data to support a potential BLA submission for isaralgagene Civapearvovec, and the timing of such submission; and other statements that are not historical fact. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to Sangamo's lack of capital resources to obtain regulatory approval for and commercialize its product candidates in a timely manner or at all, including the ability to secure a commercialization partner for ST-920; the uncertain timing and unpredictable nature of clinical trial results, including the risk that preliminary or topline data is not indicative of final results, that the therapeutic effects observed in the latest clinical data from the Phase 1/2 STAar study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civilaparvovec,including that the 52-week data from the Phase 1/2 STAAR study will not support a BLA submission and/or that the 104-week data from such study will not verify the clinical benefit of isaralgagene civicaparvovec or support FDA approval, and that the patients withdrawn from ERT will remain off ERT; All forward-looking statements about Sangamo's future plans and expectations, including Sangamo's development plans for its product candidates, are subject to Sangamo's ability to secure adequate additional funding. There can be no assurance that Sangamo and its current or potential future partners will be able to develop a clinical trial data from the Phase 1/1/2 STAAR study will not support the clinical benefit of isaralagene civaparvovovec or support FDA approval.
ナラティブの更新 • Dec 11SGMO: Accelerated Approval Pathway Is Expected To Drive Upside Through 2026Analysts have lowered their price target on Sangamo Therapeutics from $5.00 to $1.00 per share, citing a more cautious stance as they await greater clarity on a potential Fabry partnership, despite an extended cash runway and a reaffirmed accelerated approval path. Analyst Commentary Analysts are reassessing Sangamo Therapeutics with a more balanced view, emphasizing both the company’s de-risked regulatory path and the uncertainties that could weigh on execution and valuation.
Breakeven Date Change • Dec 07Forecast to breakeven in 2027The 4 analysts covering Sangamo Therapeutics expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 11% per year to 2026. The company is expected to make a profit of US$15.7m in 2027. Average annual earnings growth of 72% is required to achieve expected profit on schedule.
お知らせ • Dec 02Sangamo Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber NeuropathySangamo Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ST-503, an investigational epigenetic regulator for the treatment of intractable pain due to small fiber neuropathy (SFN), a type of chronic neuropathic pain. Fast Track Designation aims to facilitate the development and expedite the review of new therapeutics that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Companies granted this designation are given the opportunity for more frequent interactions with the FDA. These clinical programs may also be eligible to apply for Accelerated Approval and Priority Review if relevant criteria are met. ST-503 is currently being evaluated in the Phase 1/2 STAND study, where patient recruitment and enrollment are in progress. In September 2025, Sangamo presented updated nonclinical data highlighting the pharmacology and safety of ST-503 in chronic neuropathic pain at the 9th International Congress on Neuropathic Pain. The data demonstrated the durability, potency and selectivity of ST-503 in nonhuman primates, alongside a favorable safety profile, supporting its development for the treatment of chronic neuropathic pain. A copy of the presentation is available in the Presentations section of the Sangamo website. Ant antidepressantsants, anticonvulsants, opioids and topical therapies are potential treatment options, although no long-lasting or curative therapies are currently available for SFN patients, leading to a high unmet medical need for this patient population.
ナラティブの更新 • Nov 27SGMO: FDA Accelerated Pathway Will Extend Bullish Momentum Into 2026Analysts have lowered Sangamo Therapeutics’ price target from $5 to $1, citing uncertainty around future partnership deals. This is despite recent regulatory updates and an extended cash runway.
分析記事 • Nov 23Revenues Working Against Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Share Price Following 33% DiveSangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares have had a horrible month, losing 33% after a relatively good period...
お知らせ • Nov 22Sangamo Therapeutics, Inc. Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry DiseaseSangamo Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted Sangamo's request for a rolling submission and review of the Biologics License Application (BLA) for isaralgagene civaparvovec, or ST-920, a wholly owned investigational gene therapy for the treatment of adults with Fabry disease. This acceptance follows Sangamo's meeting with the FDA in October 2025 to discuss the proposed efficacy and safety data package for isaralgagene Civaparvovec where, in the meeting minutes, among other things, the FDA reiterated its October 2024 agreement to use eGFR slope as an endpoint to support an accelerated approval pathway. Sangamo presented detailed clinical data from the registrational Phase 1/2 STAAR study at the International Congress of Inborn Errors of Metabolism 2025 (ICIEM2025) in September, which demonstrated the potential for isaralgagene civilaparvovec as a one-time, durable treatment of underlying pathology of Fabry disease to provide meaningful, multi-organ, clinical benefits above current standards of care. Furthermore, the STAAR study demonstrated a positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-we weeks across allosed patients in the study, which the FDA has agreed will serve as the primary basis of approval. Isaralgagene civapARvovec has been granted Orphan Drug, Fast Track and RMAT designations from the FDA, Orphan Medicinal Product designation and PRIME eligibility from the European Medicines Agency and Innovative Licensing and Access Pathway from U.K. Medicines and Healthcare products Regulatory Agency. Sangamo plans to initiate rolling submission of the BLA to the FDA under the accelerated approval pathway later in the fourth quarter of 2025. These forward-looking statements include, without limitation, statements relating to: the safety and efficacy and therapeutic potential of isaralgagene civAParvovec, including the potential for isaralgAGene civaparvoveC, including that the 52-week data from the Phase 1/2 STAAR trial will not support a BLA submission and/or that the 104-week data from such study will not verify the clinical benefit of isaralgagene Civapec or support FDA approval, and that the patients withdrawn from ERT will remain off ERT; All forward-looking statements about Sangamo's future plans and expectations, including Sangamo's development plans for its product candidates, are subject to Sangamo's ability to secure adequate additional funding. There can be no assurance that Sangamo and its current or potential future partners.
Major Estimate Revision • Nov 14Consensus revenue estimates fall by 37%The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from US$72.3m to US$45.6m. Forecast losses increased from -US$0.291 to -US$0.397 per share. Biotechs industry in the US expected to see average net income decline 9.7% next year. Consensus price target of US$3.25 unchanged from last update. Share price fell 2.5% to US$0.45 over the past week.
ナラティブの更新 • Nov 08SGMO: FDA Approval Path Will Drive Bullish Outlook Into 2026Analysts have lowered their price target for Sangamo Therapeutics from $5 to $1. They cited a cautious outlook, pending greater clarity on a Fabry collaboration and updated guidance following the company's latest quarterly report.
Price Target Changed • Nov 07Price target decreased by 21% to US$3.25Down from US$4.10, the current price target is an average from 5 analysts. New target price is 589% above last closing price of US$0.47. Stock is down 84% over the past year. The company is forecast to post a net loss per share of US$0.42 next year compared to a net loss per share of US$0.49 last year.
Reported Earnings • Nov 06Third quarter 2025 earnings released: US$0.12 loss per share (vs US$0.045 profit in 3Q 2024)Third quarter 2025 results: US$0.12 loss per share (down from US$0.045 profit in 3Q 2024). Revenue: US$581.0k (down 99% from 3Q 2024). Net loss: US$34.9m (down 472% from profit in 3Q 2024). Revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.
お知らせ • Oct 31Sangamo Therapeutics, Inc. to Report Q3, 2025 Results on Nov 06, 2025Sangamo Therapeutics, Inc. announced that they will report Q3, 2025 results at 9:30 AM, US Eastern Standard Time on Nov 06, 2025
お知らせ • Oct 30Nasdaq Grants 180 Day Extension to Sangamo Therapeutics, Inc. to Regain ComplianceOn October 29, 2025, Sangamo Therapeutics, Inc. (the Company") received a letter (the Extension Notice") from The Nasdaq Stock Market LLC (Nasdaq") advising that the Company has been granted a 180-day extension, or until April 27, 2026, to regain compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Requirement"), in accordance with Nasdaq Listing Rule 5810(c)(3)(A). If at any time prior to April 27, 2026, the bid price of the Company's common stock, par value $0.01 per share (Common Stock"), closes at $1.00 per share or more for a minimum of 10 consecutive trading days, the Company will regain compliance with the Minimum Bid Price Requirement. The Extension Notice has no immediate effect on the listing of the Common Stock on The Nasdaq Capital Market and does not affect the Company's reporting requirements with the Securities and Exchange Commission (SEC"). As previously disclosed on the Current Report on Form 8-K filed with the SEC on May 5, 2025, the Company received a letter on April 30, 2025 from the Listing Qualifications Staff of Nasdaq indicating that, based upon the closing bid price of the Common Stock, for the preceding 30 consecutive business days, the Company was not in compliance with the Minimum Bid Price Requirement. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided 180 days, or until October 27, 2025, to regain compliance with the Minimum Bid Price Requirement. The Company intends to cure the Minimum Bid Price Requirement by April 27, 2026, however if the Company does not regain compliance with the Minimum Bid Price Requirement during this period, the Company expects that Nasdaq will provide written notification to the Company that its Common Stock will be delisted. At that time, the Company may appeal the delisting determination to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq listing rules. However, there can be no assurance that, if the Company does appeal the delisting determination by Nasdaq to the hearings panel, that such appeal would be successful. There can be no assurance that the Company will regain compliance with the Minimum Bid Price Requirement during the additional 180-day compliance period or maintain compliance with any other Nasdaq listing requirement.
分析記事 • Oct 07There's No Escaping Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Muted Revenues Despite A 28% Share Price RiseSangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares have continued their recent momentum with a 28% gain in the last...
分析記事 • Sep 23Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Are In A Position To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
ナラティブの更新 • Sep 21FDA Approval In 2026 Will Extend Fabry Gene Therapy ProspectsThe sharp increase in Sangamo Therapeutics' consensus analyst price target is primarily driven by a significantly higher future P/E expectation, indicating greater anticipated earnings growth or improved sentiment, with the fair value rising from $2.62 to $4.10. What's in the News CFO Prathyusha Duraibabu resigned, effective October 1, to join a private AI company; no disagreements cited in her departure.
ナラティブの更新 • Sep 06FDA Approval In 2026 Will Extend Fabry Gene Therapy ProspectsSangamo Therapeutics' fair value has been revised downward, primarily reflecting meaningful declines in both its forward P/E multiple and net profit margin, resulting in a lower consensus price target of $2.62. What's in the News Sangamo presented detailed data from the registrational Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920), its investigational gene therapy for adults with Fabry disease, showing a positive mean annualized eGFR slope of 1.965 mL/min/1.73m2/year in all patients followed at least 12 months.
お知らせ • Sep 04Sangamo Therapeutics, Inc. Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025Sangamo Therapeutics, Inc. announced detailed data from the registrational Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned investigational gene therapy for the treatment of adults with Fabry disease. These data were presented at the International Congress of Inborn Errors of Metabolism 2025 (ICIEM2025) in Kyoto, Japan, on September 4, 2025, in a poster presentation. Updated Phase 1/2 STAAR Study Results (as of April 10, 2025 cut-off date) Efficacy (32 dosed patients followed at least 12 months); A positive mean annualized eGFR slope of 1.965 mL/min/1.73m2/year (95% confidence interval (CI): -0.153, 4.083) at 52-we weeks was observed across all 32 dosed patients. Isaralgagene civapARvovec has been granted Orphan Drug, Fast Track and RMAT designations from the FDA, Orphan Medicinal Product designation and PRIME eligibility from the European Medicines Agency and Innovative Licensing and Access Pathway from U.K. Medicines and Healthcare products Regulatory Agency. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to Sangamo's lack of capital resources and need for substantial additional funding to execute its operating plan and to continue to operate as a going concern, including the risk that Sangamo will be unable to obtain substantial additional funding on acceptable terms or at all or collaboration partners necessary to advance its preclinical and clinical programs, in particular for its Fabry disease program and to otherwise operate as a going concern, in which case Sangamo may be required to cease operations entirely, liquidate all or a portion of its assets and/or seek protection under the U.S. Bankruptcy Code; the uncertain timing and unpredictable nature of clinical trial results, including the risk that the therapeutic effects observed in the latest clinical data from the Phase 1/2 STAAR trial will not validate the safety and efficacy of isaralgagene civapearvovec, including that the 104-week data from such study will not verify the clinical benefit of isaralgagene Civaparvovec or support FDA approval, and that the patients withdrawn from ERT will remain off ERT; the effects of macroeconomic factors or financial challenges, including as a result of the ongoing overseas conflicts, tariffs, geopolitical instability, inflation and fluctuations in interest rates, on the global business environment, healthcare systems and business and operations of Sangamo and its collaborators; the research and development process; the unpredictable regulatory approval process for product candidates across multiple regulatory authorities; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results, including the results of any regulatory trial of Sangamo's product candidates; the potential for technological developments that obviate technologies used by Sangamo; All forward-looking statements about Sangamo's future plans and expectations, including Sangamo's development plans for its product candidates, are subject to Sangamo's development plans for the treatment of adults withFabry disease.
New Risk • Aug 11New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 45% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$36m free cash flow). Shareholders have been substantially diluted in the past year (45% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$1.6m net loss in 3 years). Share price has been volatile over the past 3 months (16% average weekly change).
Reported Earnings • Aug 10Second quarter 2025 earnings: EPS and revenues miss analyst expectationsSecond quarter 2025 results: US$0.078 loss per share (improved from US$0.17 loss in 2Q 2024). Revenue: US$18.3m (up US$18.0m from 2Q 2024). Net loss: US$20.0m (loss narrowed 43% from 2Q 2024). Revenue missed analyst estimates by 42%. Earnings per share (EPS) also missed analyst estimates by 100%. Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings.
お知らせ • Aug 01Sangamo Therapeutics, Inc. to Report Q2, 2025 Results on Aug 07, 2025Sangamo Therapeutics, Inc. announced that they will report Q2, 2025 results After-Market on Aug 07, 2025
分析記事 • Jul 24Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Price Is Right But Growth Is Lacking After Shares Rocket 26%Those holding Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares would be relieved that the share price has rebounded...
New Risk • May 15New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$98.4m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (19% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$68m net loss in 3 years). Market cap is less than US$100m (US$98.4m market cap).
Major Estimate Revision • May 14Consensus revenue estimates fall by 54%The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from US$62.2m to US$28.7m. Forecast losses increased from -US$0.274 to -US$0.44 per share. Biotechs industry in the US expected to see average net income decline 13% next year. Consensus price target down from US$5.00 to US$4.10. Share price fell 33% to US$0.44 over the past week.
New Risk • May 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$69m net loss in 3 years).
Price Target Changed • May 13Price target decreased by 21% to US$4.10Down from US$5.17, the current price target is an average from 5 analysts. New target price is 791% above last closing price of US$0.46. Stock is down 19% over the past year. The company is forecast to post a net loss per share of US$0.42 next year compared to a net loss per share of US$0.49 last year.
お知らせ • May 13Sangamo Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $22.972713 million.Sangamo Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $22.972713 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 12,235,000 Price\Range: $0.5 Discount Per Security: $0.03 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 34,398,393 Price\Range: $0.49 Discount Per Security: $0.0294
お知らせ • May 07+ 1 more updateSangamo Therapeutics, Inc. to Report Q1, 2025 Results on May 12, 2025Sangamo Therapeutics, Inc. announced that they will report Q1, 2025 results After-Market on May 12, 2025
お知らせ • May 06Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry DiseaseSangamo Therapeutics announced that all dosed patients have passed one-year milestone required by U.S. Food and Drug Administration (FDA) for Accelerated Approval regulatory pathway for ST-920. Preliminary analysis of clinical data collected as of this 52-week milestone date across all 32 dosed patients indicates that the mean eGFR slope continued to remain positive, following the last clinical update at the WORLDSymposium in February 2025, with a data cutoff date of September 12, 2024. Furthermore, in April 2025, Sangamo held a productive Type B meeting with the FDA, providing Sangamo with a clear CMC pathway to a planned BLA submission in the first quarter of 2026, including clarity on plans for process validation, path to commercial specifications and the commercial launch manufacturing site.
お知らせ • May 01Sangamo Therapeutics, Inc., Annual General Meeting, Jun 12, 2025Sangamo Therapeutics, Inc., Annual General Meeting, Jun 12, 2025. Location: meetnow.global/murlfcm, United States
お知らせ • Apr 29Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)Sangamo Therapeutics, Inc. announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted nine Sangamo abstracts for presentation at the 28th ASGCT Annual Meeting being held May 13-17, 2025, in-person in New Orleans, LA and in a virtual format. Presentations will highlight the progression of Sangamo’s neurology pipeline, including advances in zinc finger epigenetic regulation, the latest innovations in capsid delivery engineering, and developments in modular integrase technology. Data presentations at the ASGCT Annual Meeting include three oral presentations that detail Sangamo’s advances in the application of zinc finger repressors (ZFRs) as a novel class of epigenetic regulation for neurological disease targets. Two presentations – including one taking place in the Presidential Symposium – showcase how Sangamo is combining its ZFR targeting the prion gene with STAC-BBB, its intravenously administered neurotropic capsid, for the treatment of prion disease, a fatal and incurable neurodegenerative disease. These presentations describe the profound survival benefits of the treatment in disease mouse models, and the sustained, brain-wide suppression of prion protein expression in both mouse and nonhuman primate models, supporting its potential as a one-time therapeutic approach for prion disease. The third presentation focuses on the advancement of ST-503, a ZFR targeting the gene encoding Nav1.7, for the treatment of intractable, chronic neuropathic pain following intrathecal delivery. Additional poster presentations at the ASGCT Annual Meeting will showcase advances in novel adeno-associated virus (AAV) capsid engineering and manufacturing for central nervous system (CNS) delivery. Topics range from second-generation STAC-BBB variants and receptor-targeted AAVs, to innovations in manufacturing and quality control, including strategies to enhance yield, purity, and stability, and improve analytical assessment of AAV products. Sangamo will also present updated data from its protein-guided MINT platform as an approach to enable engineering of large gene-sized pieces of DNA. Collectively, these abstracts highlight the versatility, durability, and translational potential of ZFR-based gene regulation across diverse neurological applications.
New Risk • Apr 07New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$67m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-US$67m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$71m net loss in 3 years). Share price has been volatile over the past 3 months (14% average weekly change).
新しいナラティブ • Apr 01Neurology IND And Fabry Agreements Will Transform Treatment Strategic partnerships and collaborations position Sangamo as a key player, enhancing revenue potential through non-dilutive capital and licensing agreements.
Reported Earnings • Mar 18Full year 2024 earnings: EPS and revenues miss analyst expectationsFull year 2024 results: US$0.49 loss per share (improved from US$1.48 loss in FY 2023). Revenue: US$57.8m (down 67% from FY 2023). Net loss: US$97.9m (loss narrowed 62% from FY 2023). Products in clinical trials Phase I: 1 Revenue missed analyst estimates by 6.8%. Earnings per share (EPS) also missed analyst estimates by 4.9%. Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.
お知らせ • Mar 07Sangamo Therapeutics, Inc. to Report Q4, 2024 Results on Mar 17, 2025Sangamo Therapeutics, Inc. announced that they will report Q4, 2024 results After-Market on Mar 17, 2025
分析記事 • Mar 04Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Looks Inexpensive After Falling 25% But Perhaps Not Attractive EnoughTo the annoyance of some shareholders, Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares are down a considerable 25% in...
お知らせ • Feb 06Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety ProfileSangamo Therapeutics, Inc. announced updated data from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease. Updated Phase 1/2 STAAR Study Results (as of the September 12, 2024 cut-off date) Safety (all dosed patients): Isaralgagene civapARvovec continued to be generally well-tolerated, with the majority of adverse events being grade 1-2 in nature. Enrollment and dosing are complete in the Phase 1/2 STAar study. In October 2024, Sangamo announced that the FDA had provided a clear regulatory pathway to Accelerated Approval for isaralgagene civAParvovec using data from ongoing Phase 1/2 STAAR trial study, avoiding the requirement for an additional registrational study and accelerating estimated time to potential approval by approximately three years. The FDA agreed in a Type B interaction that data from the ongoing Phase 1/2 STA AR study can serve as the primary basis for approval under the Accelerated Approval Program, using eGFR slope at 52 weeks across all patients as an intermediate clinical endpoint. The 52-week eGFR slope data from all enrolled patients in the Phase 1/2STAR study will be available in the first half of 2025. Sangamo believes that its zinc finger epigenetic regulators are ideally suited to potentially address devastating neurological disorders and that its capsid discovery platform can expand delivery beyond currently available intrathecal delivery capsids, including the central nervous system. These forward-looking statements include, without limitation, statements relating to: the safety and efficacy and therapeutic potential of isaralgagene Civaparvovec, including the potential for it to be a one-time, durable treatment option for Fabry disease that can improve patient outcomes; the presentation of clinical data from the phase 1/2 STAAR study; the potential for isaralgagene CivAParvovec to qualify for the FDA's Accelerated Approval program, including the adequacy of data generated in the Phase 1/2 ST-920 study to support any such approval; expectations concerning the availability of additional data to support a potential BLA submission for isaralgagene civicaparvovec, and the timing of such submission; the potential to accelerate the expected timeline to approval of isaralgagene civapearvovec; Sangamo's plans to advance discussions with the FDA and the European Medicines Agency; Factors that could cause actual results to difference include, but are not limited to, risks and uncertainties related to Sangamo's lack of capital resources to obtain regulatory approval for and commercialize its product candidates in a timely manner or at all, including the ability to secure a collaboration partner for ST-920; the uncertain timing and unpredictable nature of clinical trial results, including the risk that the therapeutic effects observed in the latest preliminary clinical data from the Phase 1/2 STAAR study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene citizensaparvovec, a fully owned gene therapy product candidate for ST-920, a wholly owned gene therapy product candidate for Fabry disease.
分析記事 • Dec 08Investors Don't See Light At End Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Tunnel And Push Stock Down 30%Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares have retraced a considerable 30% in the last month, reversing a fair...
分析記事 • Nov 20Analysts Just Made A Massive Upgrade To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) ForecastsSangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shareholders will have a reason to smile today, with the analysts making...
お知らせ • Nov 20Sangamo Therapeutics, Inc. Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic PainSangamo Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for its ST-503 program, an investigational epigenetic regulator for the treatment of intractable pain due to idiopathic small fiber neuropathy (iSFN), a type of chronic neuropathic pain. Neuropathic pain can be caused by a broad array of pathologies impacting the central or peripheral nervous systems, such as surgical trauma, spinal cord injury, nerve compression, neurological and infectious diseases, or metabolic and hereditary syndromes. ST-503 is not intended for sporadic or acute pain, but for chronic, intractable pain that completely dominates and often destroys the lives of patients over many years. The Phase 1/2 study will assess the safety and efficacy of ST-503 in addressing iSFN, a peripheral neuropathy that results in highly debilitating symptoms of burning, prickling, stabbing or “lightning-like” pain. iSFN has an estimated prevalence of at least 43,000 patients in the U.S., and more broadly, peripheral neuropathies are estimated to affect nearly 40 million Americans. Antidepressants, anticonvulsants, opioids and topical therapies are potential treatment options, although no long-lasting or curative therapies are currently available for iSFN patients, leading to a high unmet medical need for this patient population. A significant body of evidence implicates sodium channels in mediating the pathophysiology of neuropathic pain. ST-503 uses an adeno-associated virus (AAV) vector carrying an engineered zinc finger repressor (ZFR) to specifically target the human gene, SCN9A, that encodes the Nav1.7 sodium channel and is critical for pain signaling. Developing small molecules that specifically target Nav1.7 is challenging due to the high structural similarities between different sodium channels, making it difficult to achieve selectivity and avoid off-target effects. By directly targeting the SCN9A gene, ST-503 was shown to selectively reduce the expression of Nav1.7 sodium channels in sensory neurons in animal models and significantly reduce pain hypersensitivity, following a single intrathecal administration of ST-503. Sangamo’s preclinical research has shown ST-503 to be well tolerated in nonhuman primates, with substantial Nav1.7 reduction observed with no off-target effects, demonstrating the promise of ST-503 as a potential therapy for chronic neuropathic pain, regardless of cause. Sangamo is preparing for the Phase 1/2 clinical study to assess the safety, tolerability and preliminary efficacy of a one-time dose of ST-503, administered intrathecally to patients with intractable pain due to iSFN, and plans to initiate patient enrollment in mid-2025. Sangamo believes that if this study is successful, the development of ST-503 could be broadened to patient populations suffering from other types of chronic neuropathic pain.
Reported Earnings • Nov 14Third quarter 2024 earnings: EPS and revenues exceed analyst expectationsThird quarter 2024 results: EPS: US$0.051 (up from US$0.59 loss in 3Q 2023). Revenue: US$49.4m (up 426% from 3Q 2023). Net income: US$10.7m (up US$114.8m from 3Q 2023). Profit margin: 22% (up from net loss in 3Q 2023). The move to profitability was primarily driven by higher revenue. Revenue exceeded analyst estimates by 97%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 39% per year, which means it is performing significantly worse than earnings.
New Risk • Nov 14New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.07% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$179m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings are forecast to decline by an average of 0.07% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$26m net loss in 3 years). Shareholders have been diluted in the past year (17% increase in shares outstanding).
Major Estimate Revision • Nov 07Consensus revenue estimates fall by 17%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$41.2m to US$34.1m. Forecast losses increased from -US$0.53 to -US$0.554 per share. Biotechs industry in the US expected to see average net income decline 14% next year. Consensus price target up from US$3.80 to US$4.80. Share price rose 65% to US$2.81 over the past week.
お知らせ • Nov 05Sangamo Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024Sangamo Therapeutics, Inc. announced that they will report Q3, 2024 results After-Market on Nov 12, 2024
分析記事 • Oct 23What Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 26% Share Price Gain Is Not Telling YouSangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares have continued their recent momentum with a 26% gain in the last...
Seeking Alpha • Oct 21Sangamo Follow-Up: Giro-Vec And STAC-BBB? Check. Isa-Vec... Trifecta Soon?Summary Sangamo Therapeutics, Inc.'s stock surged after positive updates on two lead assets, giro-vec and STAC-BBB, with potential for significant milestone payments and partnerships. The upcoming isa-vec deal could be transformative, potentially securing Sangamo's financial stability and pushing its valuation towards $1 billion. Despite recent gains, high volatility and financial risks make SGMO a speculative investment, suitable only for risk-tolerant investors. Key risks include potential setbacks in giro-vec and isa-vec developments, which could impact Sangamo's cash flow and overall valuation. Read the full article on Seeking Alpha
Major Estimate Revision • Aug 23Consensus revenue estimates increase by 32%The consensus outlook for revenues in fiscal year 2024 has improved. 2024 revenue forecast increased from US$31.3m to US$41.2m. Forecast losses expected to reduce from -US$0.483 to -US$0.461 per share. Biotechs industry in the US expected to see average net income decline 14% next year. Consensus price target of US$3.80 unchanged from last update. Share price fell 2.5% to US$0.86 over the past week.
Reported Earnings • Aug 07Second quarter 2024 earnings: EPS and revenues miss analyst expectationsSecond quarter 2024 results: US$0.18 loss per share (improved from US$0.66 loss in 2Q 2023). Revenue: US$356.0k (down 95% from 2Q 2023). Net loss: US$36.1m (loss narrowed 68% from 2Q 2023). Revenue missed analyst estimates by 96%. Earnings per share (EPS) also missed analyst estimates by 23%. Revenue is forecast to grow 54% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 56% per year, which means it is performing significantly worse than earnings.
分析記事 • Aug 03There's Reason For Concern Over Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Massive 171% Price JumpSangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shareholders would be excited to see that the share price has had a great...
お知らせ • Jul 31Sangamo Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024Sangamo Therapeutics, Inc. announced that they will report Q2, 2024 results After-Market on Aug 06, 2024
New Risk • Jul 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$218m). Currently unprofitable and not forecast to become profitable over next 3 years (US$23m net loss in 3 years). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (US$83.3m market cap).
Seeking Alpha • Jul 23Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The RemakingSummary Sangamo Therapeutics, Inc. is almost out of cash, and as such, at risk of bankruptcy. Therefore, investing in this company is not a good idea for most investors. 3 of its assets have updates coming over the next 1–6 months that could realistically bring in a combination of ~$1B of cash & milestones over the next 12–18 months. Due to its history of burning cash and not being able to get a drug approved yet, Sangamo Therapeutics's stock price closed Monday, 07/22/24 at $0.395/s or a valuation of ~$82M. Below, I will discuss why I think the company is going to make it and possibly deliver 5-10x over the next 6–12 months. Read the full article on Seeking Alpha
分析記事 • Jun 19Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 35% Price DropUnfortunately for some shareholders, the Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) share price has dived 35% in the...
分析記事 • May 29We Think Shareholders May Want To Consider A Review Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation PackageKey Insights Sangamo Therapeutics' Annual General Meeting to take place on 4th of June CEO Sandy Macrae's total...
Major Estimate Revision • May 21Consensus EPS estimates fall by 10%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$42.8m to US$38.8m. Losses expected to increase from US$0.44 per share to US$0.48. Biotechs industry in the US expected to see average net income decline 11% next year. Consensus price target of US$3.50 unchanged from last update. Share price rose 5.2% to US$0.60 over the past week.
分析記事 • May 14This Just In: Analysts Are Boosting Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Outlook for This YearShareholders in Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) may be thrilled to learn that the analysts have just...
New Risk • May 13New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$218m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$218m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$56m net loss in 3 years). Shareholders have been diluted in the past year (21% increase in shares outstanding).
Reported Earnings • May 10First quarter 2024 earnings released: US$0.27 loss per share (vs US$0.13 profit in 1Q 2023)First quarter 2024 results: US$0.27 loss per share (down from US$0.13 profit in 1Q 2023). Revenue: US$481.0k (down 100% from 1Q 2023). Net loss: US$49.1m (down 332% from profit in 1Q 2023). Revenue is forecast to grow 49% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.
お知らせ • May 10Sangamo Therapeutics, Inc. Reports Impairment Charges for the First Quarter Ended March 31, 2024Sangamo Therapeutics, Inc. reported impairment charges for the first quarter ended March 31, 2024. For the quarter, the company reported impairment of long-lived assets of $4,349,000 compared to $20,433,000 a year ago.
お知らせ • May 03Sangamo Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024Sangamo Therapeutics, Inc. announced that they will report Q1, 2024 results After-Market on May 09, 2024
お知らせ • May 01Sangamo Therapeutics, Inc. Receives A Deficiency Notice from NasdaqOn April 24, 2024, Sangamo Therapeutics, Inc. (the Company") received a deficiency notice, or the Notice, from the Listing Qualifications Staff, or the Staff, of The Nasdaq Stock Market LLC, or Nasdaq, notifying the Company that, for the last 30 consecutive business days, the bid price of the Company's common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5450(a)(1). The Notice has no immediate effect on the listing of the Company's common stock on the Nasdaq Global Select Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until October 21, 2024, or the Compliance Date, to regain compliance with the minimum bid price requirement by having shares of the Company's common stock maintain a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days before the Compliance Date. If the Company's common stock does not achieve compliance by the Compliance Date, the Company may be eligible for an additional 180-day period to regain compliance. To qualify for the second compliance period, the Company would be required to transfer its listing to the Nasdaq Capital Market and meet the continued listing requirement for market value of publicly held shares and all other applicable initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice to Nasdaq of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. However, if it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible for the second compliance period, and the Company does not regain compliance by the Compliance Date, the Staff will provide written notification that the Company's common stock is subject to delisting. At that time, the Company may appeal the delisting determination to a hearings panel pursuant to the procedures set in the applicable Nasdaq listing rules. However, there can be no assurance that, if the Company receives a delisting notice and appeals the delisting determination by Nasdaq to the panel, such appeal would be successful. The Company intends to actively monitor the closing bid price of its common stock between now and the Compliance Date and, as appropriate, will evaluate available options to resolve the deficiency and regain compliance with the minimum bid price requirement.
お知らせ • Apr 21Sangamo Therapeutics, Inc., Annual General Meeting, Jun 04, 2024Sangamo Therapeutics, Inc., Annual General Meeting, Jun 04, 2024, at 08:30 Pacific Standard Time. Agenda: To elect the nine nominees for director named in the proxy statement, or the Proxy Statement, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2025 and until their successors are duly elected and qualified; to approve, on an advisory basis, the compensation of named executive officers, or NEOs; to approve the amendment and restatement of the Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan, or the 2018 Plan, to, among other things, increase the aggregate number of shares of common stock reserved for issuance under the 2018 Plan by 11,000,000 shares; to ratify the appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2024; and to transact such other business as may properly come before the meeting.
New Risk • Apr 19New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$98.8m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (25% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$88m net loss in 3 years). Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (US$98.8m market cap).
お知らせ • Mar 25Sangamo Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $24 million.Sangamo Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $24 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 24,761,905 Price\Range: $0.84 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 3,809,523 Price\Range: $0.84 Transaction Features: Registered Direct Offering
分析記事 • Mar 23Little Excitement Around Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues As Shares Take 36% PoundingSangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares have retraced a considerable 36% in the last month, reversing a fair...
お知らせ • Mar 22Sangamo Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $24 million.Sangamo Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $24 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 24,761,905 Price\Range: $0.84 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 3,809,523 Price\Range: $0.84 Transaction Features: Registered Direct Offering
Major Estimate Revision • Mar 20Consensus revenue estimates fall by 13%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$42.5m to US$36.9m. Forecast losses increased from -US$0.483 to -US$0.499 per share. Biotechs industry in the US expected to see average net income decline 8.2% next year. Consensus price target of US$3.50 unchanged from last update. Share price fell 11% to US$0.77 over the past week.
分析記事 • Mar 16Analysts Have Just Cut Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Estimates By 24%Today is shaping up negative for Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shareholders, with the analysts delivering...
お知らせ • Mar 14Sangamo Therapeutics, Inc. Reports Impairment Results for the Fourth Quarter Ended December 31, 2023Sangamo Therapeutics, Inc. reported impairment results for the fourth quarter ended December 31, 2023. For the quarter, the company reported Impairment of long-lived assets of $0.3 million.
Reported Earnings • Mar 13Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: US$1.48 loss per share (further deteriorated from US$1.25 loss in FY 2022). Revenue: US$176.2m (up 58% from FY 2022). Net loss: US$257.8m (loss widened 34% from FY 2022). Revenue missed analyst estimates by 3.3%. Earnings per share (EPS) also missed analyst estimates by 6.9%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 60% per year, which means it is performing significantly worse than earnings.
お知らせ • Mar 13+ 1 more updateSangamo Therapeutics, Inc. to Report Q4, 2023 Results on Mar 13, 2024Sangamo Therapeutics, Inc. announced that they will report Q4, 2023 results Pre-Market on Mar 13, 2024
